



















































































































































































were  invited  to attend  the survey on selected days  in study centers  located  in Mahé, Praslin, and La Digue. All  the 
eligible participants who did not attend were actively traced using (telephone,  local administration, announcements 








policy  in  the  interval.  Data  also  show  that  the  general  public  largely  supports  the  tobacco  control  legislation 
implemented a few years ago in Seychelles. 
 Tobacco  control  needs  to  be  strengthened  including  strict  enforcement  of  current  legislation  and  need  to 
address new issues, e.g. electronic cigarettes, shisha, measures targeting smoking among youth, etc. 
b) Blood pressure  (BP)  tended  to decrease over  time, consistent with  improved awareness,  treatment and control 
5  
rates between 1989 and 2013. Favorable  trends  likely  reflect  socio‐economic development,  increasingly diverse 
nutrition, and improved medical care. However, the level of control of BP among persons with HBP and knowledge 
on hypertension is far from optimal. 
 There  is a need  to  improve health  care  for patient with HBP,  including updated guidelines  for detection and 
treatment of hypertension, training of health professionals, extended use of home BP monitoring, etc. There is 
also a need to improve population‐based interventions, including awareness campaigns (“know your numbers”, 
“reduce  your  salt”,  etc)  and  structural measures  in  all  sectors  to  improve  choices  for  healthy  products  and 
regular physical activity (e.g. reduction of salt in locally made or imported manufactured foods).  
c) The prevalence of overweight/obesity and diabetes has markedly  increased between 1989 and 2013, consistent 
with worldwide  upward  trends  and  increasingly  globalized  food markets.  The  survey  provides  information  on 
dietary patterns in the population, which is useful to guide individual‐based and population‐based interventions. 
 Need to develop structural interventions in all sectors to improve the availability of, and access to, healthy foods 
for  all  people  and  in  different  possible  settings  (schools,  workplaces,  etc),  adequate  food  labeling,  ban  on 
advertising of unhealthy  foods  in mass media,  subsidies/taxes on healthy/unhealthy  foods,  reformulation of 
manufactured foods in terms of salt, sugar and fats, etc. Interventions in all sectors are also needed to promote 
physical  activity  in  different  settings. Health  education  programs  are  helpful  to  raise  awareness  on  healthy 
lifestyles and should target all population sub‐groups. The school setting is particularly important to empower 
healthy  choices  at  a  young age.  Specific measures  include  free water  supply  through water  fountains  in  all 
schools, healthy  food menus  in canteens, 2 or 3 hours per week of physical activity as part of  regular school 
program, etc. 
d) Knowledge on NCDs is fairly good in the population, reflecting the impact of continued health education programs 
in  the mass media  in  Seychelles  and  through  other  avenues  over  the  past  2‐3  decades.  Yet  several  areas  of 
knowledge about NCDs  should be  improved,  including knowledge on his/her own body weight, blood pressure, 







 Need to brainstorm efficient and  innovative mechanisms to provide adequate health education at the  level of 
health  care  services  (in order  to  target patients) and  through other  channels  (in order  to  target  the general 
public). 
f) The survey provides information on frequency of screening for several priority cancers. 




















Cardiovascular  diseases  (CVD)  and  other  main  noncommunicable  diseases  (NCD)  such  as  cancer,  diabetes,  and 
obstructive pulmonary disease account for more than 70% of all premature deaths in most middle income countries, 






























Vital  statistics  in  Seychelles  show  that  CVD  and  cancer  account  for  the  largest  share  of  premature mortality  and 
morbidity in Seychelles [5]. The good news is that the age‐standardized rates of CVD are decreasing in Seychelles [6], 
consistent with  trends  in  high  income  countries.  This  favorable  downward  trend  in  is  likely  related  to  the many 
programs and policies implemented over the past 2‐3 decades in the Seychelles to address NCDs, particularly strong 
tobacco  control  measures  (e.g.  comprehensive  tobacco  control  legislation  in  2009),  improved  nutrition  (i.e. 
increasingly diverse food) and free health care allowing all high risk persons to receive treatment. 
However, Seychelles experiences a rapid demographic transition so that the total number of NCD will rise over time 




in  the  population.  Population‐based  surveys  require  that  participants  are  randomly  selected  from  the  general 
population. Previous population‐based surveys of NCD risk factors were conducted in 1989, 1994 and 2004. Results of 
these surveys have been widely  reported  in overall  reports  [7‐9] and  through more  than 50 publications  that have 
focused  on  special NCD  issues  [10‐15].  The  existence  of  data  from  4  national  surveys  between  1989  and  2013  is 
unique and no country in the African region has performed more than two national NCD surveys, except Mauritius. 
Results  from  the  past  surveys  (1989,  1994,  2004)  have  shown  divergent  trends  of  NCD  risk  factors  over  time: 
downward  trend  for smoking  (good news), unchanged or decreasing  trends  for high BP and high blood cholesterol 



























































The  survey was attended by 1240 adults, with a participation  rate of 73%. Participants were  invited  to attend  the 











































The  population  aged  25‐64  has  nearly  doubled  between  1989  and  2013.  The  population  is markedly  aging with 




Age‐standardized mortality  rates  have markedly  decreased  in  the  25  year  interval  for  all  broad  cause  categories, 
including cardiovascular disease (CVD) and cancer. This means that at a given age the chance to get CVD or cancer has 
decreased over  time. This decrease  in  age‐specific  causes of mortality  is due  to  improved  living  conditions, public 

















































































































1990 1994 2004 2012
581 457 477
377
39 30 41 44




































Consistent with  regularly decreasing  age‐specific mortality between 1989  and  2013,  life  expectancy has  increased 
steadily during the past decades and reaches fairly high values in recent years. Increased life expectancy is also noted 
















y = 0.13x - 192.23



























25‐34 35‐44 45‐54 55‐64 Tota l
Men
El igible 196 202 217 215 830
Participants 111 109 150 161 531
Participation (%) 56.6 54 69.1 74.9 64
Women
El igible 204 216 222 230 872
Participants 162 168 183 196 709
Participation (%) 79.4 77.8 82.4 85.2 81.3
Total
El igible 400 418 439 445 1702
Participants 273 277 333 357 1240




1989  1994  2004  2013‐2014 
Age range  Men  Women  Men  Women  Men  Women  Men  Women  Total 
25‐34     105  123     119  142    126  149    111  161     1036 
35‐44  127  143  124  143  134  176  109  170  1126 
45‐54  145  145  132  142  158  181  150  183  1236 
55‐64  136  157  129  136  150  181  161  195  1245 
Total     513  568     504  563    568  687    531  709     4643 
The four surveys included similar total numbers of participants, i.e. 1081 in 1989, 1067 in 1994, 1255 in 2004 and 1240 
in 2013. Participation rates in the surveys in 1989, 1994 and 2004 exceeded 80% and participation in 2013 was 73%. 
These participation  rates  are  excellent  for  such  exanimation  surveys,  and  allow  generalizing  findings  to  the  entire 




numbers of participants  in each of  four 10‐year age categories  (i.e. random sex and age stratified sample  from  the 
total  population  aged  25‐64  years).  The  sample  sizes  in  each  of  the  four  surveys  are  sufficiently  large  to  provide 
sufficient statistical power  to assess  the main objectives of  the surveys,  i.e.  the prevalence of risk  factors and  their 
trends over time. 
Of note,  similar methods were used  in all  four  surveys  in  relation  to  the  sampling  strategy  (sex and age  stratified 
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Interventions  to  reduce  body  weight  at  the  individual  level  often  have  little  efficacy,  except  bariatric  surgery. 
Therefore, weight  control  interventions  should  focus  on  the  societal  causes  of  the  obesogenic  environment  and 
include  interventions  in all  sectors  (e.g. education, agriculture,  finance,  transports, nutrition,  food  industry, etc)  to 
enable people to chose healthier diets,  including adequate  food  labeling, tax/subsidies on healthy/unhealthy foods; 














































































































































































cardiovascular  diseases  and  lung  cancer  between  1989  and  2013.  Decreasing  prevalence  of  smoking  (men)  likely 
reflects  the  high  profile  tobacco  control  program  in  Seychelles  since  the  late  1980s,  which  includes  continued 
awareness programs, fairly high tax on tobacco products (>65% of total cost of cigarette packet in 2014), and impact 


















As  the  first  country  that  has  ratified  the  Framework  Convention  for  Tobacco  Control  in  the  African  region,  and 























of  homebrew  drinking  in  Seychelles.  It was  indeed mostly  persons  of  lower  SES who  used  to  drink  inexpensive 
homebrews  in past  surveys, and drank  it  in  large amounts. Homebrew drinking has virtually disappeared  in  recent 
years and consumption of alcohol now almost entirely relies on commercial beverages, which are highly taxed. High 
price of alcohol beverages is a most effective measure against heavy drinking. One could even expect a reversal of the 



























































decreased over  time, but  is still substantial  in 2013  (nearly 11% of men  in 2013). However,  the prevalence of both 
moderate drinking (1‐2 drinks per day) and marked drinking (3‐5 drinks per day) has increased over time in both men 
and women.  
Of note, alcohol  intake was not assessed  in 1994  for persons drinking  less  than once weekly and the prevalence of 
category 1‐25 ml/day  is therefore underestimated  in 1994. This has  impact on estimation of the prevalence of  light 
drinking but has only little impact on estimates of total alcohol consumption. 










































































































































However,  while  the  prevalence  of  heavy  drinking  (>5  drinks  per  day  on  average)  has  decreased  over  time,  the 
proportions of all adults drinking light or moderate alcohol amounts has increased among both men and women.  
Because the population has largely increased over time, the total numbers of heavy drinkers in the population (mainly 
men)  remains  high,  and  the  numbers  of moderate  drinkers  (1‐2  or  3‐5  drinks  per  day  on  average)  have  largely 
increased. This  implies  large and  further  increasing numbers of health, social and other alcohol‐related problems  in 
the population, e.g. larger numbers of drunk drivers on the roads.  
A further important problem is that alcohol is often consumed along a binge drinking pattern (i.e. high intake on few 




















A  significant  proportion  of  people  eat  (more  healthy)  brown  bread,  and more  often  among  higher  vs.  lower  SES 
persons. This proportion should be increased through awareness campaigns. 
   
















































The proportions of persons not removing fat  is high, and tends to be  lower  in female vs. male, older vs. young, and 




The  consumption  of  olive  oil  (a  healthy  oil  rich  in  mono‐unsaturated  fatty  acids)  is  unexpectedly  high  in  the 


























Intakes  of  meat,  processed  meat,  potatoes,  potato  chips,  and  pasta  are  still  low  (although  likely  largely  higher 
compared to past years). Consumption of poultry is quite frequent. Intake of salted and sweet snacks is substantial.  





(e.g. bread,  cheese, milk, breakfast  cereals, etc) which are not  substantially present  in  rice and  fish. However,  the 
current diet also includes substantial intake of nutrient‐poor and energy‐rich food items (e.g. large amounts of sugar 
28  
added  in  tea/coffee,  soft drinks,  juices  in packets,  salted  and  sweet  snacks, processed meat, etc). These nutrients 
contribute  large  amounts of  sugar,  salt,  saturated  fats or  trans  fats, which  are  important  causes of  cardiovascular 





Most  importantly,  promoting  a  healthy  diet  requires  interventions  in multiple  sectors  aimed  at  enabling  healthy 
choices by all people. This includes, inter alia, differential subsidies/taxes on healthy/unhealthy food items; structural 




The WHO member states,  inclusive Seychelles, have agreed  in 2014 on  the  target of a 10% decrease of salt  intake 
between 2010 and 2025. Other documents emphasize the need for healthy nutrition  in terms of  increased fruit and 
vegetables and reduced consumption of added sugar, salt, saturated fats and trans fats.  













































All  students  in  all  classes  in  all  schools  should  have  at  least  2  (or  better  3)  compulsory  classes  of  PA  per week, 
emphasizing on PA that is suitable for all students (including girls, overweight children, etc) vs. sportive performance 
(the latter can be better provided through activities outside of regular school classes). 
The WHO member states,  inclusive Seychelles, have agreed  in 2014 on the target of a 10% relative decrease  in the 
prevalence of insufficient PA.  






































































































































Figure  5.  Age‐standardized  proportions  of  persons  aware  of  having HBP  (among  all  persons  aged  25‐64),  treated 

















































































The  proportion  of  persons  knowing  a  number  for  their  own  BP  values  is  very  low,  despite  several  “know  your 























































Systolic BP did not  increase over  time, and diastolic BP decreased, despite a marked  increase of  the prevalence of 
obesity  (a main risk factor of HBP).  In parallel, the proportions of hypertensive  individuals who are aware of having 
HBP  (among all persons with HBP), who are treated  for HBP  (among those who are aware of having HBP) and who 
have BP  lowered  to  target BP  values  (among  those patients  treated  for HBP) have markedly  increased over  time, 
consistent with marked  improvement  in  health  care  for HBP  over  time. However,  the  proportion  of  hypertensive 
persons who  have  BP  adequately  controlled  is  still  low  and  there  is  a  need  to  further  strengthen  health  care  to 
antihypertensive  patients.  This  includes  revision  of  guidelines,  training  of  health  care  professionals,  innovative 
measures to improve adherence of patients to treatment (e.g. appointments for follow up visits, seeing same doctors 
over time, etc). 
There  is  also  a  need  for multisectoral  interventions  to  decrease  BP  in  the  entire  population,  particularly  through 
decreased salt  intake  in the diet  (e.g. reformulation of manufactured foods to reduce the content  in salt; fiscal and 




30%  relative  reduction  of  salt,  ii)  at  least  50%  of  eligible  persons  receiving  treatment  for NCD  conditions  such  as 
hypertension  (this goal  is nearly achieved by 2013) and  iii) 80% availability of  technologies and essential medicines 
required to treat NCD (this goals is achieved since many years in Seychelles).  
Awareness  campaigns need  to  further  to  sensitize  the population about BP e.g.  “know  your numbers”  campaigns, 
nutrition messages, etc). 







men.  Cholesterol  increases with  age,  particularly  in women, which  is  related  to  both  hormonal  changes  in  older 
women and  to overweight. There  is also an  inverse  J shape  relation between mean cholesterol and calendar years 



































Seychelles  (age  25‐64)  has  largely  increased  because  of  the  increasing  and  aging  population. While  around  2500 
persons  aged  25‐64  received  cholesterol  lowering  treatment  in  2013,  treatment  should  also  be  considered  for  a 
substantial proportion of the around 6000 adults with high  levels  (≥6.2 mmol/l) and  for some of the approximately 
11’000 persons with borderline high levels (particularly those persons at high CVD risk, including a majority of persons 
with diabetes). These numbers do not include persons older than 65, who are not included in this survey. Treatment 































































































































































































































Individual based measures  to  improve cholesterol  levels  can be very effective, and  include  screening of persons at 
high  risk  of  CVD,  adequate  counseling  on  healthy  lifestyles,  and  treatment  of  persons  with  high  CVD  risk.  This 













































































































































Figure  4.  Age‐standardized  prevalence  of  impaired  fasting  blood  glucose  (5.6‐6.9  mmol/l)  and  diabetes  (FBG  ≥7 
mmol/l or treatment) by sex and survey year, age 25‐64 
             





















































































































































The prevalence of diabetes has markedly  increased between 1989 and 2013,  reaching 11.9%  in men and 10.8%  in 
women  in  2013.  These proportions may be  slightly overestimated  because  diabetes  is  based  on one  single  blood 
glucose measurement and high values of fasting blood glucose were not confirmed with a repeat test on a separate 
day. The increase in the prevalence of diabetes is closely linked with the increasing prevalence of obesity. 
Measures  to  reduce  the  burden  of  diabetes  include  strengthened  health  care  to manage  existing  diabetes  cases, 
including  improved detection and  treatment  (e.g. updated guidelines,  training of health professionals, measures  to 
improve  adherence  to  treatment,  etc).  Improved management  of  diabetes  patients must  be  comprehensive with 
management of all other risk factors, particularly healthy lifestyle, including physical activity, healthy diet, refraining of 
tobacco use, and management of high blood pressure, dyslipidaemia, other risk factors, and target organ damages.  
Because  diabetes  cannot  be  cured,  preventive  measures  must  be  emphasized,  which  includes  multisectoral 
population wide  interventions  to  promote  a  healthy  diet  and  physical  activity  (listed  in  the  sections  on  BMI  and 
physical activity). 










Figure 1. Age‐standardized prevalence of  risk  factors  in successive surveys and  linear  relative change during  the 24 
year interval, age 25‐64 
 




Comment.  The  age‐standardized  prevalence  of main  risk  factors  between  1989  and  2013  decreased,  or  did  not 
increase (which  is good news) for some risk factors (smoking, blood pressure, cholesterol), but the total numbers of 
persons with  these  risk  factors  still  increased  substantially  because  of  the  ageing  and  increasing  population.  For 










































































































































































































































While  the  frequency of breast  cancer  screening  in women without  a  family history of breast  cancer  is debatable, 






















































































  Men             Women           
agecat 1989 1994 2004 2013 
Abs. Dif
in 24 yr
Rel. Dif  
2013/19









25-34 22.9 23.3 24.4 24.6 1.8 8.0   23.2 24.8 26.4 27.8 4.3 18.7 
35-44 23.9 24.8 25.7 27.7 3.6 15.1   26.9 27.3 28.6 29.3 2.5 9.5 
45-54 23.2 24.4 26.8 27.0 4.0 17.1   27.1 28.6 29.4 30.6 3.2 12.0 
55-64 23.3 24.3 25.6 26.2 2.8 12.2   27.6 28.1 30.3 29.5 2.2 8.1 
25-64 Ahmad 23.3 24.1 25.5 26.3 3.0 12.8   25.9 26.9 28.3 29.1 3.2 12.5 
BMI ≥25                           
f25-34 21.0 26.9 41.3 42.3 22.7 108.4   30.1 41.5 55.0 56.5 26.3 87.4 
35-44 37.8 42.1 55.2 67.0 29.7 78.5   57.3 61.5 67.6 72.9 15.3 26.8 
45-54 29.7 45.5 63.3 64.0 34.1 115.1   58.6 73.9 76.8 86.3 23.9 40.8 
55-64 24.3 42.5 50.7 57.1 29.7 122.5   70.1 69.9 84.0 80.0 13.1 18.6 
Prev 25-64 Ahmad 28.2 38.1 51.8 56.7 28.5 100.9   51.1 59.4 68.5 72.0 20.4 40.0 
Prev 25-64 actual pop 26.5 36.5 51.7 57.6 31.3 118.1   46.6 55.6 66.9 72.7 25.8 55.3 
N in actual pop 25-64 3'496 6'107 10'569 14'015 10'482 299.8   5'453 8'546 13'664 17'822 12'287 225.3 
BMI ≥30                           
25-34 3.8 5.9 9.5 14.4 10.4 273.2   8.9 16.2 22.8 31.1 21.0 235.0 
35-44 4.7 9.9 15.7 32.1 25.9 547.6   29.4 28.0 37.5 39.4 12.0 41.0 
45-54 2.8 7.6 22.8 21.3 20.5 744.5   26.9 38.0 39.8 50.3 20.3 75.3 
55-64 6.6 11.0 16.0 18.0 11.2 168.8   33.1 36.0 48.1 40.5 9.7 29.3 
Prev 25-64 Ahmad 4.3 8.3 15.4 21.6 17.2 399.8   22.9 27.9 35.1 39.4 16.4 71.6 
Prev 25-64 actual pop 4.3 8.1 15.2 22.0 17.6 411.8   19.9 26.0 34.2 40.1 19.9 100.1 
N in actual pop 25-64 564 1'351 3'103 5'342 4'740 839.7   2'625 4'351 7'001 9'753 7'004 266.8 
Smoking daily                           
25-34 47.6 27.7 30.2 31.5 -11.2 -23.5   6.5 3.5 4.0 7.5 1.4 21.9 
35-44 40.2 32.3 32.1 25.7 -12.1 -30.2   9.8 6.3 4.0 3.5 -5.9 -60.0 
45-54 62.1 40.2 31.0 26.7 -31.8 -51.2   12.4 9.9 3.9 3.3 -9.7 -77.8 
55-64 55.9 55.0 29.3 28.6 -32.0 -57.3   12.7 9.6 3.3 5.6 -7.8 -61.1 
Prev 25-64 Ahmad 50.3 36.5 30.8 28.3 -19.7 -39.3   9.8 6.8 3.9 5.1 -4.7 -48.1 
Prev 25-64 actual pop 49.5 35.2 30.9 28.1 -18.8 -37.9   9.1 6.1 3.9 4.9 -4.0 -44.0 
N in actual pop 25-64 6'545 5'887 6'313 6'830 472 7.2   1'070 930 796 1'206 106 9.9 
Somking daily/weekly                           
25-34 52.4 31.9 42.9 41.4 -4.0 -7.7   7.3 4.9 6.7 13.0 6.1 82.8 
35-44 42.5 37.9 39.6 30.3 -10.1 -23.7   10.5 8.4 6.3 5.3 -5.0 -48.1 
45-54 64.1 44.7 35.4 30.0 -31.0 -48.4   13.1 10.6 5.5 4.4 -9.0 -68.9 
55-64 58.8 58.9 32.7 32.3 -31.6 -53.7   14.0 10.3 3.9 6.2 -8.5 -60.3 
Prev 25-64 Ahmad 53.4 41.1 38.5 34.1 -16.6 -31.1   10.7 8.1 5.8 7.7 -3.0 -28.0 
Prev 25-64 actual pop 53.1 39.8 39.0 33.7 -16.1 -30.2   9.9 7.6 6.0 7.4 -2.5 -24.8 
N in actual pop 25-64 7'013 6'658 7'970 8'198 1'500 21.4   1'312 1'274 1'220 1'797 433 33.0 
Occasional smoking                           
25-34 4.8 4.2 12.7 9.9 7.2 150.4 0.8 1.4 3 6 4.6 569.8 
35-44 2.4 5.6 7.5 4.6 2.1 88.0 0.7 2.1 2 2 0.8 117.9 
45-54 2.1 4.5 4.4 3.3 0.8 37.4 0.7 0.7 2 1 0.6 91.8 
55-64 2.9 3.9 3.3 3.7 0.4 14.7 1.3 0.7 1 1 -0.7 -52.6 
Prev 25-64 Ahmad 3.2 4.6 7.7 5.9 3.1 98.9   0.8 1.3 2.0 2.6 1.7 210.0 
Prev 25-64 actual pop 3.5 4.6 8.1 5.6 2.7 77.0   0.8 1.4 2.1 2.5 1.7 201.1 
N in actual pop 25-64 468 771 1'657 1'369 1'028 219.5   97 212 428 617 519 535.0 
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Cig/day (smoker)                           
25-34 12.9 13.3 9.2 7.1 -6.5 -50.8   4.1 6.4 8.8 4.6 0.8 19.0 
35-44 13.1 12.6 9.4 6.0 -7.4 -56.1   8.9 8.3 7.6 11.5 2.2 24.8 
45-54 12.9 10.5 13.1 9.3 -2.2 -17.2   7.8 9.6 6.9 4.7 -3.9 -49.7 
55-64 11.2 12.3 10.8 6.6 -4.8 -42.6   6.2 4.4 9.3 6.3 1.7 27.6 
25-64 Ahmad 12.7 12.3 10.4 7.2 -5.5 -43.3   6.7 7.3 8.1 6.8 0.3 4.0 
Ethanol (ml)         
25-34 59.2 38.6 32.7 34.1 -21.7 -36.7 4.9 2.3 3.9 10.0 5.5 112.2 
35-44 67.0 67.8 38.6 30.5 -41.5 -62.0 8.1 2.6 3.8 7.9 0.9 11.2 
45-54 97.6 62.2 43.0 37.5 -55.2 -56.6 14.5 2.6 4.3 5.7 -5.9 -40.8 
55-64 65.5 56.0 52.4 26.9 -34.9 -53.3 8.0 6.5 2.1 4.4 -4.3 -53.6 
25-64 Ahmad 71.3 55.2 40.0 32.7 -37.2 -52.2   8.5 3.2 3.7 7.5 -0.1 -1.0 
Ethanol ≥30 ml/day         
25-34 55.2 25.2 37.3 41.4 -5.0 -9.0 4.9 2.8 4.7 9.9 5.4 111.4 
35-44 54.3 50.0 35.8 34.9 -21.1 -38.9 9.1 2.1 2.8 7.6 -0.1 -1.4 
45-54 59.3 39.4 40.5 45.3 -9.6 -16.3 11.7 2.8 4.4 4.4 -5.0 -42.7 
55-64 55.9 42.6 39.3 30.4 -22.3 -39.9 7.0 5.9 2.8 3.1 -4.3 -61.4 
Prev 25-64 Ahmad 56.0 38.4 38.0 38.6 -13.5 -24.1   8.0 3.1 3.8 6.8 -0.2 -2.3 
Prev 25-64 actual pop 55.8 37.1 37.8 38.8 -12.7 -22.8   7.3 3.0 3.8 6.8 0.3 4.2 
N in actual pop 25-64 7'370 6'203 7'730 9'433 2'474 33.6   858 468 776 1'659 872 101.7 
Ethanol ≥75 ml/day                         
25-34 32.4 15.1 11.1 12.6 -16.7 -51.7 1.6 1.4 0.7 1.9 0.0 2.5 
35-44 30.7 29.0 11.9 7.3 -25.9 -84.3 3.5 1.4 0.6 1.2 -2.1 -58.8 
45-54 40.0 22.7 17.1 14.7 -22.3 -55.7 6.2 1.4 1.1 0.0 -5.1 -81.8 
55-64 33.1 20.9 20.0 9.3 -20.2 -61.2 3.2 2.9 0.0 0.5 -3.2 -101.4 
Prev 25-64 Ahmad 33.8 21.8 14.2 11.0 -21.2 -62.7   3.5 1.7 0.6 1.0 -2.3 -65.7 
Prev 25-64 actual pop 33.3 21.1 13.8 11.1 -20.6 -61.9   3.1 1.6 0.6 1.0 -2.0 -64.7 
N in actual pop 25-64 4'403 3'532 2'814 2'698 -1'634 -37.1   361 247 132 237 -129 -35.9 
Systolic BP                           
25-34 124.3 125.5 124.6 128.6 3.6 2.9   113.6 116.7 113.9 117.2 2.1 1.8 
35-44 131.6 136.2 127.8 138.5 3.2 2.5   124.9 127.7 120.9 125.2 -2.1 -1.7 
45-54 137.8 139.8 135.6 141.9 2.3 1.6   136.0 137.9 132.3 133.8 -3.9 -2.9 
55-64 143.2 149.6 142.7 145.3 -0.9 -0.7   144.8 145.8 139.1 140.3 -6.2 -4.2 
25-64 Ahmad 132.7 135.9 131.1 137.3 2.4 1.8   127.2 129.6 124.4 127.2 -1.9 -1.5 
Diastolic BP                           
25-34 82.8 83.9 81.3 75.6 -7.4 -9.0   73.7 77.4 76.4 73.4 -1.1 -1.5 
35-44 87.3 91.0 84.1 84.1 -5.4 -6.2   83.1 84.6 80.2 79.0 -5.2 -6.2 
45-54 90.6 92.7 89.2 86.3 -5.2 -5.7   88.0 88.8 85.5 82.0 -6.5 -7.4 
55-64 89.9 94.0 90.6 84.9 -6.1 -6.8   90.3 90.2 86.4 81.3 -9.3 -10.3 
25-64 Ahmad 87.1 89.6 85.5 82.0 -6.1 -7.0   82.4 84.2 81.3 78.3 -4.9 -5.9 
BP >=140/90                           
25-34 25.7 26.1 20.6 17.1 -9.4 -36.6   8.1 9.2 6.0 4.3 -4.5 -55.0 
35-44 44.9 51.6 33.6 39.4 -11.0 -24.4   33.6 31.5 19.9 17.6 -17.5 -52.1 
45-54 54.5 61.4 49.4 48.0 -10.2 -18.8   43.4 43.7 39.2 33.9 -10.0 -23.0 
55-64 65.4 74.4 64.7 54.7 -13.8 -21.1   63.1 63.2 48.6 47.2 -18.6 -29.5 
Prev 25-64 Ahmad 44.5 49.6 38.4 36.9 -10.8 -24.3   32.7 32.5 24.8 22.1 -11.8 -36.0 
Prev 25-64 actual pop 40.4 46.3 36.3 37.8 -6.0 -14.8   27.5 27.6 22.2 22.4 -6.2 -22.4 
N in actual pop 25-64 5'343 7'740 7'434 9'207 3'103 58.1   3'221 4'242 4'533 5'496 2'014 62.5 
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BP ≥140/90 or Rx                           
25-34 25.7 26.1 23.0 18.9 -7.1 -27.6   8.1 9.9 10.1 8.7 0.3 4.1 
35-44 45.7 52.4 38.8 44.0 -6.3 -13.7   34.3 31.5 30.1 28.8 -5.0 -14.5 
45-54 55.2 62.1 56.3 55.3 -2.5 -4.4   47.6 47.2 51.9 54.1 7.3 15.4 
55-64 67.6 76.0 72.7 68.3 -1.5 -2.2   66.2 66.2 69.6 72.3 6.5 9.8 
Prev 25-64 Ahmad 45.2 50.2 43.5 42.7 -4.8 -10.7   34.4 34.1 35.4 35.6 1.5 4.4 
Prev 25-64 actual pop 41.1 46.9 41.3 43.8 0.2 0.4   28.8 28.9 32.0 36.1 7.5 25.8 
N in actual pop 25-64 5'424 7'838 8'449 10'666 4'615 85.1   3'378 4'439 6'531 8'839 5'420 160.4 
BP ≥160/100                           
25-34 12.4 13.4 5.6 1.8 -12.0 -97.0   1.6 4.2 1.3 0.6 -2.1 -128.6 
35-44 18.1 27.4 7.5 15.6 -9.2 -50.8   7.0 13.3 5.1 2.9 -6.9 -98.3 
45-54 24.1 30.3 22.2 18.7 -8.1 -33.7   21.4 24.6 16.0 9.8 -13.4 -62.7 
55-64 27.9 47.3 24.7 23.0 -13.6 -48.6   28.7 29.4 18.8 20.0 -11.0 -38.3 
Prev 25-64 Ahmad 19.3 27.0 13.2 13.1 -10.6 -54.8   12.3 15.7 8.7 6.7 -7.5 -61.5 
Prev 25-64 actual pop 17.8 25.3 12.1 13.7 -8.5 -47.7   10.1 13.2 7.5 6.6 -5.2 -51.4 
N in actual pop 25-64 2'357 4'225 2'477 3'332 136 5.8   1'180 2'026 1'541 1'621 147 12.4 
Told to have HBP (whole pop)                        
25-34 9.5 5.0 8.7 11.7 3.7 38.7   6.5 9.9 8.1 9.3 1.6 24.2 
35-44 17.3 19.4 18.7 26.6 8.0 46.2   19.6 18.2 23.3 21.2 3.1 15.8 
45-54 23.4 22.0 37.3 36.0 16.0 68.3   31.0 28.9 40.9 40.4 12.2 39.5 
55-64 29.4 29.5 47.3 47.8 21.8 74.0   40.8 41.9 59.1 60.0 22.2 54.4 
Prev 25-64 Ahmad 18.3 17.1 24.6 27.6 10.8 59.1   21.6 22.0 28.6 28.4 8.0 36.8 
Prev 25-64 actual pop 16.4 15.5 22.8 28.3 13.0 79.4   18.5 19.4 25.6 28.6 10.8 58.7 
N in actual pop 25-64 2'168 2'594 4'663 6'885 4'825 222.6   2'161 2'973 5'229 6'996 4'930 228.1 
Treated for HBP (in whole pop)                       
25-34 1.0 0.0 4.8 2.7 3.1 322.0   1.6 2.1 5.4 5.6 4.5 274.4 
35-44 9.4 4.8 13.4 15.6 8.7 91.7   7.7 5.6 16.5 14.1 9.2 119.7 
45-54 7.6 12.1 25.3 23.3 17.4 229.8   17.9 19.7 31.5 31.7 15.6 87.1 
55-64 12.5 17.8 36.7 41.0 30.5 244.3   22.3 25.7 50.3 54.4 35.7 160.0 
Prev 25-64 Ahmad 6.8 7.2 17.3 17.6 12.6 184.9   10.6 11.2 22.1 22.3 13.7 129.0 
Prev 25-64 actual pop 5.6 6.0 15.9 18.1 14.1 252.4   8.7 9.0 19.5 22.2 15.2 174.5 
N in actual pop 25-64 739 1'009 3'244 4'406 3'935 532.4   1'022 1'382 3'978 5'449 4'716 461.4 
Treated & BP <140/90 (in whole pop)                       
25-34 0 0 2 2 2.4     0 1 4 4 4.4   
35-44 1 1 5 5 4.8 477.2   1 0 10 11 12.1 1207.0 
45-54 1 1 7 7 7.2 715.8   4 4 13 20 17.1 428.1 
55-64 2 2 8 14 12.6 631.6   3 3 21 25 25.1 837.4 
Prev 25-64 Ahmad 0.9 0.9 5.0 6.0 5.9 693.3   1.7 1.8 10.6 13.2 13.0 759.1 
Prev 25-64 actual pop 0.7 0.7 4.8 6.1 6.1 899.2   1.4 1.5 9.8 13.4 13.3 979.1 
N in actual pop 25-64 90 125 976 1'494 1'515 1689.6   159 230 1'993 3'286 3'338 2099.0 
Cholesterol                           
25-34 4.91 5.13 5.08 4.78 -0.2 -3.3   4.92 5.11 5.03 4.61 -0.3 -6.7 
35-44 5.26 5.43 5.65 4.90 -0.3 -5.4   5.21 5.33 5.18 4.94 -0.3 -5.7 
45-54 5.05 5.37 5.48 5.23 0.1 2.9   5.66 6.18 5.64 5.09 -0.7 -13.2 
55-64 5.09 5.56 5.57 5.04 -0.1 -2.2   5.85 6.47 6.18 5.46 -0.5 -9.0 
25-64 Ahmad 5.1 5.3 5.4 5.0 -0.1 -2.3   5.3 5.6 5.4 5.0 -0.4 -8.4 
HDL cholesterol                           
25-34 1.41 1.57 1.38 1.23 -0.2 -16.8   1.32 1.52 1.34 1.28 -0.1 -9.2 
35-44 1.40 1.52 1.29 1.11 -0.3 -24.8   1.41 1.52 1.37 1.27 -0.2 -13.2 
45-54 1.49 1.50 1.33 1.23 -0.3 -19.5   1.41 1.58 1.39 1.37 -0.1 -7.9 
55-64 1.44 1.54 1.45 1.23 -0.2 -16.0   1.36 1.56 1.37 1.32 -0.1 -8.8 
25-64 Ahmad 1.4 1.5 1.4 1.2 -0.3 -19.5   1.4 1.5 1.4 1.3 -0.1 -10.0 
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Triglycerides                           
25-34 1.13 1.36 0.92 1.03 -0.2 -21.8   0.76 0.96 0.78 0.85 0.0 -0.1 
35-44 1.19 1.47 1.27 1.37 0.1 5.7   0.92 0.99 0.89 0.90 -0.1 -6.4 
45-54 1.20 1.59 1.27 1.37 0.0 0.9   0.91 1.25 1.00 0.98 -0.1 -5.9 
55-64 0.99 1.50 1.34 1.23 0.1 10.3   1.11 1.46 1.17 1.14 -0.1 -9.2 
25-64 Ahmad 1.1 1.5 1.2 1.2 0.0 -3.5   0.9 1.1 0.9 0.9 0.0 -5.2 
Chol ≥5.2                           
25-34 35.9 40.7 42.3 26.6 -8.7 -24.3   36.7 40.0 36.2 24.5 -12.6 -34.4 
35-44 43.9 54.2 56.0 33.6 -10.3 -23.4   41.9 52.2 48.3 35.3 -8.5 -20.4 
45-54 41.3 54.5 57.6 49.7 6.7 16.1   64.8 80.9 61.7 42.2 -28.2 -43.6 
55-64 39.2 57.8 55.6 38.6 -3.8 -9.7   70.2 80.9 70.4 53.7 -19.5 -27.8 
Prev 25-64 Ahmad 39.9 50.6 51.9 35.9 -4.8 -12.0   50.3 59.8 51.3 36.6 -16.2 -32.3 
Prev 25-64 actual pop 39.0 49.3 51.6 36.7 -2.9 -7.5   47.5 55.2 49.3 36.7 -12.6 -26.5 
N in actual pop 25-64 5'152 8'246 10'551 8'924 3'655 70.9   5'565 8'474 10'063 8'997 3'169 57.0 
Cholesterol ≥6.5                           
25-34 5.8 12.7 8.9 3.7 -4.0 -68.5   10.0 10.0 11.4 3.1 -5.9 -58.6 
35-44 13.8 19.2 21.6 10.3 -3.3 -23.8   14.0 13.8 9.7 9.6 -5.1 -36.7 
45-54 9.8 18.2 20.9 15.4 4.7 48.3   21.8 41.2 21.1 8.9 -20.2 -92.3 
55-64 9.2 28.1 18.1 12.0 -2.9 -31.7   27.8 45.0 41.3 20.2 -10.4 -37.4 
Prev 25-64 Ahmad 9.6 18.4 16.8 9.6 -1.6 -16.8   16.9 24.2 18.2 9.2 -9.7 -57.6 
Prev 25-64 actual pop 8.7 17.8 16.7 10.0 -0.3 -3.9   15.4 20.7 16.2 9.1 -7.8 -50.4 
N in actual pop 25-64 1'149 2'972 3'413 2'445 1'050 91.4   1'808 3'177 3'316 2'227 229 12.7 
Rx for chol.                           
25-34     0.0 0.9           0.0 1.9     
35-44     0.0 7.3           0.0 2.9     
45-54     1.3 6.7           1.7 8.7     
55-64     1.3 7.5           2.2 16.4     
Prev 25-64 Ahmad     0.5 5.1           0.8 6.2     
Prev 25-64 actual pop     0.6 5.4           0.8 6.2     
N in actual pop 25-64     134 1'303           188 1'508     
Chol ≥5.2 or Rx                           
25-34 35.9 40.7 42.3 26.6 -8.7 -24.3   36.7 40.0 36.2 24.5 -12.6 -34.4 
35-44 43.9 54.2 56.0 40.2 -4.3 -9.8   41.9 52.2 48.3 35.9 -8.0 -19.1 
45-54 41.3 54.5 58.9 55.0 11.9 28.9   64.8 80.9 62.2 48.6 -22.2 -34.3 
55-64 39.2 57.8 56.3 45.0 2.2 5.7   70.2 80.9 71.5 65.3 -8.6 -12.3 
Prev 25-64 Ahmad 39.9 50.6 52.3 40.1 -0.9 -2.2   50.3 59.8 51.6 40.2 -12.9 -25.6 
Prev 25-64 actual pop 39.0 49.3 51.9 41.0 1.2 3.0   47.5 55.2 49.5 40.3 -9.2 -19.5 
N in actual pop 25-64 5'152 8'246 10'625 9'983 4'642 90.1   5'565 8'474 10'112 9'874 3'983 71.6 
Glucose                           
25-34 4.73   5.23 5.15 0.46 9.8   4.67   5.12 4.94 0.32 6.9 
35-44 5.35   6.12 5.77 0.50 9.4   5.01   5.49 5.57 0.58 11.6 
45-54 5.38   6.43 6.50 1.18 21.8   5.48   5.99 6.00 0.55 10.0 
55-64 5.63   6.83 6.56 1.03 18.4   6.36   7.02 6.53 0.27 4.2 
25-64 Ahmad 5.21   6.03 5.87 0.73 14.1   5.24   5.75 5.63 0.44 8.3 
Glucose ≥5.6                           
25-34 14.3   16.8 19.8 5.4     8.1   6.7 5.6 -2.5 -30.9 
35-44 23.6   44.8 44.0 21.8     19.6   18.2 25.3 4.9 25.0 
45-54 29.0   54.4 60.7 32.6     26.2   38.1 41.5 15.7 59.9 
55-64 35.3   54.4 62.1 27.2     44.6   63.0 54.4 11.8 26.4 
Prev 25-64 Ahmad 23.8 0.0 39.7 43.2 32.1     21.7 0.0 26.7 27.7 16.0 73.7 
Prev 25-64 actual pop 21.8 0.0 38.4 44.5 34.5     18.8 0.0 23.3 28.1 17.7 93.8 
N in actual pop 25-64 2'882 0 7'864 10'825 9'858     2'207 0 4'761 6'895 5'923 268.4 
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Glucose ≥7.0                           
25-34 0.0   0.8 0.0 0.1 -   0.8   1.3 1.9 1.0 126.6 
35-44 6.3   9.7 7.3 1.5 23.6   3.5   4.5 6.5 2.8 81.3 
45-54 10.3   11.4 18.7 7.6 73.9   8.3   9.4 13.1 4.5 54.7 
55-64 10.3   20.8 21.1 11.4 111.1   15.3   23.8 21.5 7.0 45.8 
Prev 25-64 Ahmad 5.9   9.1 9.9 4.2 70.6   5.7   7.9 9.1 3.4 58.5 
Prev 25-64 actual pop 4.6   8.3 10.5 5.9 130.5   4.7   6.6 9.1 4.3 90.0 
N in actual pop 25-64 602   1'707 2'551 1'931 320.8   553   1'351 2'233 1'639 296.2 
Gluc ≥7.0 or Rx (in whole pop)                       
25-34 0.0   1.6 0.0 0.3 -   0.8   2.0 2.5 1.7 - 
35-44 6.3   9.7 10.1 4.0 62.9   3.5   4.5 7.1 3.4 96.4 
45-54 11.0   12.7 20.7 8.9 80.8   9.0   11.6 14.2 5.1 57.3 
55-64 11.0   22.7 24.8 14.3 129.7   16.6   26.5 28.2 12.1 73.0 
Prev 25-64 Ahmad 6.2   10.0 11.8 5.7 91.9   6.1   9.1 10.8 4.7 77.2 
Prev 25-64 actual pop 4.8   9.1 12.4 7.6 158.5   5.0   7.6 10.7 5.6 110.7 
N in actual pop 25-64 631   1'865 3'021 2'348 372.1   588   1'554 2'633 1'994 338.8 
Aware (in whole pop)                       
25-34 0.0 2.0 0.0 1.0 0.1     1.0 2.0 2.0 2.0 0.8 77.2 
35-44 2.0 1.0 4.0 6.0 4.6 231.6   3.0 2.0 3.0 7.0 4.1 135.7 
45-54 6.0 5.0 6.0 10.0 4.1 67.8   4.0 6.0 7.0 7.0 2.7 68.4 
55-64 7.0 12.0 15.0 19.0 11.1 158.4   8.0 15.0 18.0 21.0 11.7 146.5 
Prev 25-64 Ahmad 3.1 4.1 5.1 7.5 4.1 132.3   3.4 5.1 6.2 7.8 4.0 116.5 
Prev 25-64 actual pop 2.4 3.5 4.4 7.8 4.9 201.6   2.9 4.4 5.2 7.6 4.3 146.6 
N in actual pop 25-64 323 725 897 1'886 1'418 439.3   343 674 1'059 1'865 1'450 422.9 
Rx for diabetes                           
25-34 0.0 1.7 0.0 0.0 -0.7 -   0.0 0.7 2.0 1.2 1.4 - 
35-44 0.0 0.8 3.0 4.6 4.7 -   0.7 2.1 2.3 3.5 2.4 348.2 
45-54 3.4 3.8 5.1 8.7 5.1 147.1   2.8 3.5 7.2 5.5 3.4 122.9 
55-64 3.7 11.6 13.3 17.4 11.9 323.0   7.0 13.2 17.1 19.5 11.6 165.6 
Prev 25-64 Ahmad 1.4 3.6 4.3 6.2 4.3 301.1   2.0 3.9 5.8 6.0 3.9 192.1 
Prev 25-64 actual pop 1.1 3.3 3.7 6.4 4.6 421.5   1.6 3.2 4.9 5.7 4.0 249.1 







# topic Questions Answers categories 
1 admin Subject survey ID  n 
2 admin Discrepency in ID by questionnaire, lab or data entry text 
3 admin Date survey (dd-mmm) date 
4 admin Sex 1: M 2: F 
5 admin Age years 
6 admin Island M: mahe, P:praslin D:La Digue 
7 admin District abbreviation district abbreviation 
8 admin District district 
9  Telephone 1: yes; 0: no 
10 admin Email 1: yes; 0: no 
11 admin From census, see xls sample  
12 admin From census, see xls sample  
13 admin From census, see xls sample  
14 admin From census, see xls sample  
15 admin From census, see xls sample  
16 admin From census, see xls sample  
17 admin From census, see xls sample  
18 admin Time entry in survey, same as BP entry (secretary) hh:mn 
19 admin Time start questionnaire, same as BP1,2,3 (nurse) hh:mn 
20 admin In which language do you want to answer questions ? 
1: creole;  
2: english;  
3: french 
21 admin Which survey(s) ?  
1: no 
2: i dont know/don't remember 
3: yes, but i dont remember which ones;  
4: 1989; 
5: 1994;  
6: 2004;  
22 ses What is the highest level of education you have completed ? 
1: i did not complete obligatory school;  
2: i completed obligat school (prim/sec);  
3: i did a vocational school;  
4: i did polytechnic, A levels, or similar;  
5: i did university or equivalent 
23 ses Do you currently live alone or with a partner? (irrespective of marital status) 
1: i live with my husband/wife (married) 
2: i live with a partner ("menaz");  
3: i live with a parent 
3: i currently live alone  
24 ses How many children do you have? nb kids 
25 ses How many people, including children and yourself, are currently living in your household (at least 4 days per week)? n 
26 ses How many rooms are there in your house/flat where you currently live, including living room, but not including  kitchen, bathroom, toilets or verandah? n 
27 ses What is your current  occupation (job) (it you are not working now, what was your last job)? text : 
28 ses Category assessed by interviewer among following (current or past occupation): 
1: professional;  
2: qualified non-manual (teacher);  
3: semiqualified non-manual (clerk);  
4: qualified manual (trained mechanic);  
5: semiqualified manual (some training);  
6: nonqualified (laborer);  
7: fisherman/farmer;  




Which of the following best describes your main work situation over the past 12 
months (also before "pensioner")? 
1: government or parastatal employee;  
2: non goverment employee;  
3: self-employed;   
4: not currently working but able to work;  
5: unable to work;  
6: housewife/man (homemaker);  
7: retired/pensioned;  
8: other 
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30 ses What is your personal earnings per month, on average (incl. all allowances, benefits, etc)?  Is it:  
1: <3000;  
2: 3000-5000;  
3: 5000-8000;  
4: 8000-15'000;   
5: >15'000;  
9: refuses to answer 
31 ses What is the approximate monthly earnings of your partner? Is it: 
1: <3000;  
2: 3000-5000;  
3: 5000-8000;  
4: 8000-15'000;   
5: >15'000;  
6: i dont live with a partner 
7: my partner doesn't work 
9: refuses to answer 
32 ses Do you, or your partner, own the place (flat, appartment, house) where you live?If rent monthly amount 
1: yes, myself 
2: yes, my partner 
3: yes, shared myself and my partner 
4: yes, family member 
5: no (rent) 
33 ses [if rental] Monthly rental (Sey rupees; 1$=12 SR) n 
34 ses How often have you travelled abroad in relation to your work during the past 5 years? 
1: never;  
2: 1-3 times;  
3: more than 3 times 
35 ses Not accounting for work purposes, how often have you travelled abroad to visit family of for holidays during the past 5 years? 
1: never;  
2: 1-3 times;  
3: more than 3 times 
36 tobacco Smoking category 1: current; 2:occasional; 3:ex; 4:never 
37 tobacco Have you ever smoked cigarettes, cigars, cigarillos, pipe or shisha? 1: yes  2: no        (→ tob17) 
38 tobacco Do you currently smoke cigarettes daily?  1: yes 2: no        (→ tob5) 
39 tobacco [current smoker] How many cigarettes do you smoke each day on average? n 
40 tobacco [current smoker] Did you try to stop smoking during the past 12 months? 1: yes       (→ tob9) 2: no        (→ tob9) 
41 tobacco [If not a daily smoker] Do you smoke cigarettes occasionally? 1: yes 2: no        (→ tob7) 
42 tobacco [occasional smoker] How many cigarettes do you smoke in one week on average?  n     (→ tob9) 
43 tobacco [If not a current or occasional smoker] Did you ever smoke cigarettes daily? 1: yes 2: no        (→ tob9) 
44 tobacco [ex smoker]: How many years ago did you stop smoking? n (years; if 2 months: 0.2) 
45 tobacco How old were you when you first started to smoke cigarettes [>2 packs in total]? n (age) 
46 tobacco Did you ever use nicotine gums or pills (e.g. bupropion) to help quit smoking? 1: yes 2: no 
47 tobacco Do you currently smoke pipe, cigars, cigarillos, hand-rolled cigarettes, or shisha? 1: yes 2: no      (→ tob16) 
48 tobacco [if yes] Do you currently smoke pipe? 
1: daily;  
2: occasionally;  
3: no 
49 tobacco [if yes] Do you currently smoke cigars or cigarillos? 
1: daily;  
2: occasionally;  
3: no 
50 tobacco [if yes] Do you currently smoke hand rolled cigarettes? 
1: daily;  
2: occasionally;  
3: no 
51 tobacco [if yesl] Do you currently smoke shisha? 
1: daily;  
2: occasionally;  
3: no 
52 tobacco Did you ever used electronic cigarettes for more than 1 week? 
1: yes, now;  
2: yes, in the past;  
3: no, never 
53 tobacco Did you ever chew or sniff tobacco regularly or occasionally? 
1: yes, currently;  
2: yes, in the past;  
3: no, never 
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54 tobacco During the past 7 days, did anyone smoke in your home when you were present? 
1: yes 
2: no 
55 tobacco [During the past 7 days, did anyone smoke in enclosed areas in your workplace when you were present? 
1: yes 
2: no 
56 tobacco Have you ever heard of current legilslation for tobacc control in Seychelles 1:yes; 2: no 
57 tobacco Do you approve the ban on smoking in all enclosed places, including working places and restaurants, as per law in Seychelles ? 
1: i fully agree;  
2: i somehow agree;  
3: i don't agree (smoking should be allowed 
in enclosed places) 
58 diet 
In a typical week, on how many days do you eat fruit (fresh or can; local or 
imported), such as mango, banana, starfruit,  ripe papay, orange, apple, pear, 
grape, etc [card] 
n (0-7) 
59 diet How many  servings ("portion") of fruit do you eat on one of those days? nb servings 
60 diet 
In a typical week, on how many days do you eat vegetables on average, such as 
legumes, tomato, carrot, bred, brinzel, ziromon, green papay, green beens, salad 
(do not include lentils or gro maze) [card] 
n (0-7) 
61 diet On one of those days, how many servings of vegetables do you eat ? nb servings 
62 diet In a typical week, on how many days do you eat rice on average? n (0-7) 
63 diet On those days, do you eat rice generally on one or on two meals (lunch and/or dinner) 
1: 1 meal;  
2: 2 meals 
64 diet In a typical week, on how many days do you eat pasta (spaghetti or macaroni) ? n (0-7) 
65 diet In a typical week, on how many days do you eat bread, whether fresh, toasted or sandwiches ? n (0-7) 
66 diet When you eat bread at home, how often do you use brown bread? 
1: never;  
2: sometimes;  
3: often;  
4: always 
67 diet In a typical week, on how many days do you eat potatoes including in curry, stew or other dishes, but not accounting for chips/french fries? n (0-7) 
68 diet In a typical week, on how many days do you eat french fries ("frit")? n (0-7) 
69 diet In a typical week, on how many days do you eat breakfast cereals, such as cornflakes, oatmeal, weetabics, others? n (0-7) 
70 diet In a typical week, on how many days do you eat salad, think of tomato, letuce, watercress, tomato, carrots, cabbage, cucumber, 'patol', 'margoz', and others? n (0-7) 
71 diet When you eat salad, do you add vinaigrette (with oil) or oil (do not inlcude "piman")? 
1: yes 
2: no 
72 diet In a typical week, on how many days do you eat "gro manze"  (breadfruit, cassava, sweet potato, cooked banana, etc) ? n (0-7) 
73 diet In a typical week, on how many days do you eat lentils? n (0-7) 
74 diet In a typical week, on how many days do you eat "satini" (papay, fisiter, ziromon, brinzel,..)? n (0-7) 
75 diet In a typical week, on how many days do you eat cheese (natural, sliced, paste) or yoghurt? n (0-7) 
76 diet 
In a typical week, on how many days do you drink milk or flavored milk, or use 
drink (breakfast cereals, etc) on average, not accounting for milk added in 
tea/coffee ? 
n (0-7) 
77 diet When buying milk in packet ("dile pake") or powdered milk ("dile an bwat"), which one do you buy  most often? 
1: whole milk;  
2: semi-skimmed milk;  
3: skimmed milk 
4: i dont pay attention 
78 diet In a typical week, on how many days do you eat fish on average, fresh, frozen or in can? n (0-7) 
79 diet On those days, do you have generally fish on one or on two meals (lunch, dinner)? 
1: 1 time per day;  
2: 2 times per day 
80 diet When you cook fish at home, how often do you fry your fish? 
1: most of the times: 
2: often;  
3: rarely or never 
81 diet In a typical week, on how many days do you eat poultry? n (0-7) 
82 diet 
In a typical week, on how many days do you eat fresh or frozen red meat? (pork, 
beef, lamb, but do not account for chicken or processed meat, bacon, sausage, 
ham, lunchon meal, cornedbeef) 
n (0-7) 
83 diet In a typical week, on how many days do you eat processed meat such as sausages, bacon, corned beef, ham, lunchon meat? n (0-7) 
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In a typical week, on how many days do you eat salted snacks such as gato 
piman, samosa, banana/cassava chips/ breadfruit chips, peanuts, pizza, 'pate'  
(baked meat), corn snacks (Doritos) ? 
n (0-7) 
86 diet In a typical week, how often do you eat salted fish (pwason sale) including smoked fish? n (0-7) 
87 diet 
In a typical week, on how many days do you eat sweet snacks or dessert, such 
as mutay, gato banann, chocolate, biscuits, ice-cake, ice-cream, sweets, cakes, 
etc? 
n (0-7) 
88 diet Did you take vitamins pills or dietary supplements in the past 4 weeks? 1: yes 2: no 
89 diet [if yes] Which vitamin(s) or dietary supplements? text :  
90 diet Which type of oil or fat do you use most often for cooking at home? 
1: turkey oil;  
2: other veg oil (sunflower, soy, peanut);  
3: olive oil;  
4: margarin;  
5: butter;  
6: other; which? 
91 diet Which type of fat do you use most often to spread on bread? 
1: butter;  
2: margarin;  
3: other  
4: i dont spread on bread 
92 diet Do you use olive oil when cooking or to add in salad? 
1: never;   
2: rarely;  
3: once or twice a week;  
4: more than twice a week 
93 diet In a typical month (4 weeks), how often do you use coconut at home (dile koko or other forms of coconut) when preparing meals?  
1: less than once per month 
2: a few times but less than weekly 
3: 1-2 times in a week 
4: on 3 or more days per week 
94 diet In a typical week, on how many days do you have tea on average (black tea, green tea, citronel, camomille, etc)? n (0-7) 
95 diet On such days, how many cups of tea do you have per day on average?  nb cups/d 
96 diet In a typical week, on how many days do you have coffee? n (0-7) 
97 diet On such days, how many cups of coffee do you have per day on average?  nb cups/d 
98 diet  When you have tea or coffee, how many spoons of sugar do you add in each cup? (teaspoons)  n (0 if not) 
99 diet When you have tea/coffee, do you add milk? 
1: yes, full milk;  
2: yes, skimmed or semi-skimmed milk;  
3: no, i dont add milk 
10
0 diet 
In a typical week, on how many days do you have lemonades/soft drinks (Coke, 





On such days, how many small bottles or glasses do you have per day on 
average?  nb 5dl bottles or large glass per day 
10
2 diet 
In a typical week, on how many days do you have fruit juice in packet ("juice dan 
pake") on average? n (0-7) 
10
3 diet 
On such days, how many small packets/glasses of juice do you have per day on 
average?  nb cups/3 dl bottles/packets per day 
10
4 diet 
In a typical week, on how many days do you have fresh juice (not in a packet) on 
average? n (0-7) 
10
5 diet 
In a typical week, on how many days do you drink water on average (soda, 
bottles, tap water)? n (0-7) 
10
6 diet On such days, how many glasses of water do you drink per day on average?  nb glasses 3 dl/day (bot. 5 dl=2 glasses) 
10
7 diet 
In a typical week, on how many days do you have  "energy" drinks such as 
RedBull, KiddyBell, PussyDrink, DarkDug, Monster,Glucozade, etc? n (0-7) 
10
8 diet How often do you add salt (or Aromat) to your food at the table? 
1: never;  
2: sometimes;  
3: often;  
4: always 
10
9 diet How important to you is lowering the salt content in your diet? 
1: not important;  
2: a bit important;  
3: very important  
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11
0 diet How often do you have take-away meals? 
1: most workdays of the week;  
2: several days per week;  
3: a few times per month;  
4: rarely  
11
1 diet What best describes where you get your lunch most often? 
1: from a takeway, shop, or canteen;  
2: i bring lunch from home;  
3: i have lunch at home most of the time 
11
2 diet 
Do you read labels on food packages to help you decide what you buy, for 
example to look for salt, sugar or fat  content (don't count for "expiry date")? 
1: never;  
2: rarely;  




Have you ever drunk alcohol beverages such as beer, wine, spirit or other 
alcohol drinks? 
1: yes 
2: no     (→  pa1) 
11
4 oh 
Do you currently drink alcohol beverages such as beer, wine, spirit or other other 
alcoholic drinks at least once per month? 
1: yes 
2: no     (→  pa1) 
11
5 oh 
On average, on how many days in a month do you drink at least one alcohol 
drink?  n (0-31) 
11
6 oh 
On average, how many alcohol drinks (beer, wine, spirit, etc) do you have per 
day between Monday and Thursday, think of any type of alcohol drinks?  nb drinks/day 
11
7 oh 
On average, how many alcohol drinks (beer, spirit, wine, etc) do you have on a 
typical Friday?  nb drinks/day 
11
8 oh On average, how many alcohol drinks do you have on a typical Saturday?  nb drinks/day 
11
9 oh On average, how many drinks do you have on a typical Sunday?  nb drinks/day 
12
0 oh 
On special occasions such as celebrations, pay days, end of the month, 
weddings, etc, how many alcohol drinks can you have in total in one day? (can 
review this questtion after Q on weekly consomption) 
 nb drinks/day 
12
1 oh 
Now, think of your alcohol consumption in a whole week, including weekdays + 
weekends.  
How many bottles/cans of beer (not Guiness) do you drink in 1 week, on 
average? 
 nb bottles beer/wk 
12
2 oh 
How many bottles of Guinness (not another beer) do you drink in 1 week, on 
average? nb bottles guinness/wk 
12
3 oh How many glasses of wine (2 dl) do you drink in 1 week, on average? nb glasses wine/wk (1 bottle=4 glasses) 
12
4 oh 
Not accounting for alcopops or liquor, how many pegs of spirit (whisky, 
takamaka, rhum, vodka) do you drink in 1 week, on average? nb pegs /wk (peg = 0.25 dl; 30/bottle) 
12
5 oh 
How many small glasses  of liquor such as Irish coffee, Amarula, Martini, Porto, 
etc, do you drink in 1 week on average (alcohol content-15-20%) nb small glasses/wk 
12
6 oh 
How many bottle/cans (3dl) of alcopops/flavored/mixed alcohol drinks (Smirnoff 
Ice, Baccardi Breezer, etc) do you drink in 1 week, on average?  nb bottles alcopops/wk 
12
7 oh 
In the past 12 months, what was the largest amount of drinks you had on one 
single day, accounting for all types of drinks alltogether? 
nb drinks (3dl beer=2dl wine/liquor=0.25dl 
pirit=3 dl homebrew)  
12
8 oh 
In a typical month (30 days), on how many days do you drink more than 5 
(men)/4 (women) standard drinks per day, on average? (card: 1beer=1glass 
wine/liquor=1peg whisky) 
 n (0-30) 
12
9 oh Do you drink baka, kalou or lapire at times?  
1: yes 
2: no     (→  pa1) 
13
0 oh 
How many bottles (0.5l) of baka do you drink in 1 week, on average? (Assess if 
botles 0.5 or 1.5 l) nb bottles (0.5l) /wk 
13
1 oh How many bottles of kalou do you drink in 1 week, on average? nb bottles (0.5l) /wk 
13
2 oh How many bottles of lapire do you drink in 1 week, on average? nb bottles (0.5l) /wk 
13
3 oh 








Alcohol intake based on weekly basis adjusted for number of weeks drinking per 
month 
oh adjusted: ohtoth*1 for ohdays 21+; 
ohot*0.75 for ohdays14-21; ohtot*0.5 of 




What of the following best suits your physical activity pattern in relation to doing 
work in your workplace or at home?   
1: Sitting always or most often 
2: Often walking, standing up or carying light 
weights  
3: Walking or standing up a lot, or regularly 
carying heavy weights 
13
6 PA 
PA at WORK. Now i am going to ask you about the time you spend doing 
different types of physical activity in a typical week. We will talk about PA in three 
situations: activity related to doing work, walking to places, and leisure activity.  
 
Think first about PA you spend doing work (at the worplace, at home, or any 
other place). Think ofwork as the things you have to do for paid or unpaid work, 
household chores, fishing, gardening, farming, etc. In answering the following 
questions, "vigorous-intensity activities" are activities that require hard physical 
effort and cause large increases in breathing or heart rate, while "moderate-
intensity activities" are activities that require moderate physical effort and cause 




Does your work (at work, at home, etc) involve vigorous-intensity activity that 
causes large increases in breathing or heart rate, like carrying of lifting heavy 
loads, digging or contruction, for at least 10 min continuously?  
1: yes 
2: no        (→  pa5) 
13
8 PA 
In a typical week, on how many days do you do vigorous-intensity activity as part 
of doing  your usual work? (probe what work is about for people, hosuewife, 




How much time do you spend doing vigorous-intensity activity as part of doing 
your   work on a typical day? nb min/day 
14
0 PA 
Does your work (at your working place, at home, etc) involve moderate-intensity 
activity, that causes small increases in breathing or heart rate, such as brisk 
walking, lifting light weights, gardening, etc), for at least 10 min continuously? 
1: yes 
2: no        (→ pa8) 
14
1 PA 
In a typical week, on how many days do you do moderate-intensity activities as 
part of your  work? n (0-7) 
14
2 PA 
How much time do you spend doing moderate-intensity activities at work on a 
typical day? nb min/d 
14
3 PA 
TRAVEL to and from PLACES. The next questions exclude the physical 
activities that you have already mentioned.  
Now i would like to ask you about the usual way you travel to and from places. 




Do you walk (or use a bicycle) for at least 10 min continuously to get to and from 
such places? 
1: yes 
2: no      (→ pa11) 
14
5 PA 
 In a typical week, on how many days do you walk continuously for at least 10 
min  to get  to and from places? n (0-7) 
14
6 PA How much time do you spend walking to/from places on a typical day?  nb min/d 
14
7 PA 
RECREATIONAL ACTIVITIES. The next questions exclude physical activities 
you do for work or to go to places that you have already mentioned.  





Do you do any vigorous-intensity sports, fitness or recreational ("leisure") 
activities that cause large increase in breathing or heart rate like running, 
football, weight lifting, cycling, swimming, cycling, etc, for at least 10 min 
continuously? 
1: yes 
2: no     (→ pa14) 
14
9 PA 
In a typical week, on how many days do you do vigorous-intensity sports, fitness 
or  recreational activities? n (0-7) 
15
0 PA 
How much time do you spend doing vigorous-intensity sports, fitness or  
recreationnal activities  on a typical day?  nb min/d 
15
1 PA 
Do you do any moderate-intensity sports, fitness or recreational activities that 
cause a small increase in breathing or heart rate such as brisk walking, light 
swimming, easy cycling, etc, for at least 10 min continuously? 
1: yes 
2: no      (→ pa17) 
15
2 PA 
In a typical week, on how many days do you do  moderate-intensity sports, 
fitness or  recreational (leisure) activities? n (0-7) 
15
3 PA 
How much time do you spend doing moderate-intensity sports, fitness or 
recreational activities on a typical day?  nb min/d 
15
4 PA 
In a typical weekday, how many hours do you spend watching TV, working on a 
computer, or using Internet, per day?  n (hours/day, if 30 min = 0.5 hour) 
15
5 PA 
In a typical weekend, how many hours do you spend watching TV, working on a 
computer, or using Internet, per day?  n (hours/day, if 30 min = 0.5 hour) 
15
6 PA 
How long does it take to walk between your house and the next bus stop (in 




How often do you take a bus to go to work, shop, church, etc? No value for La 
Digue (no bus) 
1: most of the time;  
2: often;  




How often do you go to work with a private vehicle? No value for La Digue (no 
car) 
1: most of the time;  
2: often;  




Does anyone in your household have a car or a pickup? No value for La Digue 
(no car) 
1: no;  
2: yes, in the family;  
3: yes, it is my own. 
16
0 BP Have you ever heard of blood pressure or hypertension ("tansyon o")? 
1: yes 
2: no  
16
1 BP 
Can you tell me at least one or two values of your own BP, even approximate? 
Sys BP? n 
16
2 BP Tells own dia BP n 
16
3 BP Tells 1/2 values for own BP 1: yes; 2: no 
16
4 BP 
Can you tell me one or two figures, even approximate, for the upper limit for 
normal BP? Systolic BP n 
16
5 BP Tells normal dia n 
16
6 BP Tells 1 or 2 value for nornal BP 1: yes; 2: no 
16
7 BP Tells right normal BP 1: yes; 2: no 
16
8 BP In general, do you think that someone can feel when BP is high? 
1: never;  
2: sometimes;  




9 BP In general, for how long people with high BP should take pills to reduce their BP? 
1: a few days;  
2: a few months;  
3: several years;  
4: DNK 
17
0 BP When was the last time you had your BP checked by a health officer? 
1: <12 months;  
2: 1-5 yr;  
3: > 5yr 
17





Were you told by a doctor or another health professional  that you have high BP 
("tansyon o")? 
1: yes 
2: no      (→ diab1) 
17
3 BP [yes] How many years ago were you first told that you had high blood pressure? n (years; if 6 months=0.5) 
17
4 BP 
[yes] Do you take a medication for HBP (over past 2 weeks)? ("prescription", 
adherence is tested with bp13) 
1: yes 
2: no       (→ bp14) 
17
5 clinic Treatment for HBP taken this morning, asked on Lab Form by Q officer 1: yes; 0 no 
17
6 BP 
[if Rx] Who prescribed your current medication for high blood pressure most 
often? 
1: clinic/hospital goverment dr;  
2: private dr;  
3: abroad 
17
7 BP [if Rx] When you went to the dr to chek you BP, did you see the same dr? 
1: always the same dr;  
2: often the same dr;  
3: rarely the same dr; 
17
8 BP 
[if Rx] It is difficult to not forget to take pills every day. On average, how 
frequently  do you miss (voluntarily of involuntarily) your medication for high BP 
in a typical week?  
1: i forget very rarely;  
2: i forget on 1-2 days in a week;  
3: i forget on 3 or more days in a week 
17
9 BP 
Have you consulted a traditional practitioner ("okenn dimoun ki donn  lafresisan") 
for your BP ? 
1: yes 
2: no      
18
0  Are you taking any traditional medicine "lafresisan" for your diabetes? 
1: yes 
2: no      
18
1 BP 
Are you taking any traditional medicine "lafresisan" for your blood pressure?   
Which 'lafresisan' are you taking? text :  
18





3 diab When did you last have your blood sugar checked? 
1: <12 months ago;  
2: 1 or more years ago 
3: never, DNK 
18
4 diab 
Have you ever been told by a doctor or a health worker that you had high blood 
sugar or diabetes? 
1: yes 
2: no    (→ chol1) 
18
5 diab How many years ago were you first told that you had diabetes?  n (years; if 6 months=0.5; 1 month:0.1) 
18








8 diab Did you take insulin  today? assessed in LabForm y /n 
18
9 diab Did you take pills for DM taken this morning? assessed by lab, in LabForm y /n 
19
0 diab 
[if Rx] It is difficult to not forget to take pills every day. On average, how 
frequently do you miss your medication for diabetes in a typical week?  
1: i forget very rarely;  
2: i forget on 1-2 days in a week;  
3: i forget on 3 or more days in a week 
19
1 diab 
Have you consulted a traditional practitioner ("okenn dimoun ki donn lafresisan") 
for your diabetes? 
1: yes 
2: no      
19
2 diab Are you taking any traditional medicine "lafresisan" for your diabetes? 
1: yes 
2: no      
19
3 diab [if lafresisan] Which 'lafresisan' are you taking? text : 
19
4 diab 





5 chol Have you ever heard of blood cholesterol or "lagres dan disan"? 
1: yes 
2: no     (→ wei1) 
19
6 chol Have you ever had your blood cholesterol checked? 
1: yes 
2: no or DNK 
19
7 chol 










Let's talk now about your body weight.  
How would you describe your weight ? 
1: largely too high;  
2: a little too high;  
3: about right (byen, bon);  
4: a little too low;  
5: much too low 
20
0 weight Do you take concrete measures to control your weight, currently? 
1: no, i don't think much about it;  
2: yes, i make some efforts to control my 
weight;  




In this drawing, which figure best reflects how you think you look with regards to 
your weight?  n (1-9) 
20
2 weight 
Which figure best represents how you would like to look with regards to weight, 
ideally?  n (1-9) 
20
3 weight Which figure best reflects the ideal weight of a person of the other sex?  n (1-9) 
20
4 stress 
Stress can impact on your physical health, including BP. Stress can be related to 
both positive or negative events.  
Have you experienced positive events during the past 12 months, such as 
finding a new job, wedding, birth of a child, or any other event that can generate 





Have you experienced negative events during the past 12 months, such as job 
loss, divorce, death in the family, or any other event that can generate a 





I will now ask you 4 questions on your stress in relation to your work, your family, 
your financial situation and the environment where you live.    
First, on a scale of 10 (0 not stressed at all, 10 extremely stressed), how would 
you define your "stress level", during the past 12 months, in relation to your work 
(i.e. work for pay)? No data if no work 
 n (0-10) (if >=5 provide one reason) 
20




[if paid work] With regard to your paid work, how do you feel about the way you 
can organize it  on a day-to-day basis: 
1: i have little control on how i can organize 
my daily work 
2: i have some control on how i can organize 
my daily work 
3: i have quite a lot of conrol on how i 
organize my daily work 
20





On a scale of 10 (0 not stressed at all, 10 extremely stressed), how would you 
define your "stress level", during the past 12 months, in relation to your family, 
friends or neighbours (social level - not noise, etc)? 
 n (0-10) (if >=5 provide one reason) 
21
1 stress If stress>=5: Can you tell me about reason of this social stress text 
21
2 stress 
On a scale of 10 (0 not stressed, 10 extremely stressed), how would you define 
your "stress level", during the past 12 months, in relation to the place where you 
live, including noise, pollution, or other external circumstances (i.e. not social 
aspects)? 
 n (0-10) (if >=5 provide one reason) 
21
3 stress If stress>=5: Can you tell me about reason of this  stress due to environment text 
21
4 stress 
On a scale of 10 (0 not stressed at all, 10 extremely stressed), how would you 
define your "stress level", during the past 12 months, in relation to your financial 
situation? 
 n (0-10) (if >=5 provide one reason) 
21
5 stress If stress>=5: Can you tell me about reason of this  stress due to your finances text 
21
6 stress 
During the past 12 months, did you have problems paying your routine bills, such 
as for food, water, electricity or telephone (not acccounting for big loans for 
house, car, etc)? 
1: never;  
2: sometimes;  




Let's turn to your health in general.  
Would you say your health is?  
1: poor;  
2: fair ("not too good" "pa tro bon";  
3: good:  




Does your health limit you in physical activities of moderate intensity that you 
might do in a typical day, such as carrying a grocery bag, sweeping at home, or 
moving a light piece of furniture ? If so, how much? 
1: yes, i am limited a lot;  
2: yes, i am limited a little;  
3: no, i am not limited at all 
21
9 health 
Does your health  limit you in carrying out physical activities of vigorous intensity 
that you might do during a typical day, such as carrying heavy loads, climbing 
several flights of stairs or climbing a steep path? If so how much? 
1: yes, i am limited a lot;  
2: yes, i am limited a little;  
3: no, i am not limited at all 
22
0 health 
Does your health limit you in walking small distances, such as walking to the next 
bus stop or to the next shop? If so, how much? 
1: yes, i am limited a lot;  
2: yes, i am limited a little;  
3: no, i am not limited at all 
22
1 health 
Does your health limit you in climbing stairs, like when you came this morning to 
our office? 
1: yes, i am limited a lot;  
2: yes, i am limited a little;  
3: no, i am not limited at all 
22
2 health 
During the past 4 weeks, did you have any physical pain that interfered with your 
activities at work or at home? 
1: yes, i am limited a lot because of pain;  
2: yes, i am limited a little because of pain;  
3: no, not i am not limited because of pain  
22
3 health 
Now, think of energy you have to do usual things. During the past 4 weeks, did 
you have a feeling of general weekness, tiredness, or lack of energy (fay, fatige, 
mank lenerzi) ? If so, how often? 
1: yes, i lacked energy most of the time;  
2: yes, i lacked energy some of the time;  
3: no, i didn't lack energy 
22
4 health 
[yes] If you lacked energy some or most of the time: Would you say the fatigue 
was mostly? 
1: rather physical (dan lekor);  
2: rather psychological (dan latet);  
3: both physical and psychological 
22
5 health 
Now, think of being sometimes down or depressed. During the past 4 weeks, 
how often did you feel emotionally "down" or "depressed"? 
1: i felt down or depressed often;  
2: i felt depressed some of the time;  
3: no, i did not feel depressed at all 
22
6 health 
Now think of your interactions with other people. During the past 4 weeks, did 
you reduce your social activities, like visiting friends or relatives, because of any 
physical health or emotional problem?  Would you say:  
1: yes, a lot;  
2: yes, a litte;  
3: no 
22
7 health How was  your appetite recently? 
1: my appetite was as usual;  
2: diminished;  
3: increased 
22
8 health Have you lost or gained weight involuntary during the last 12 months? 
1: yes, i lost weight 
2: yes, i gained weight: 
3: no, my weight did not change much 
22
9 health 
[If yes]: how much weight have di you gain or lose during the past 12 months 




Not accounting for hypertension or diabetes, do you suffer from any medical 
condition for which you take a medical treatment during the past 4 weeks? Likely 





Do you have any chronic  medical condition(s)/disease(s) which recurrently 
bother(s) you ? Write any chronic conditions (even without treatment, like ) text : 
23
2  List all of your medications (from Q, lab form, and Dr) text 
23








5 health syst 
Were you admitted to a hospital in Seychelles or abroad during the past 12 
months for any reason (at least one night in hospital)? 
Info for this Q was extended during contact with Dr to include all chronic 
conditions written in Dataform 
1: yes, in Seychelles 
2: yes, abroad 
3: yes, both in Seychelles and abroad 
4: no    
23
6 health syst 
During the past 12 months, approximately how many times did you go to a health 




7 health syst 
During the past 12 months, approximately how many times did you go to a 
private doctor for any medical, surgical condition, or accident?  n 
23
8 health syst 
Did you ever go abroad for medical care, which was advised and paid for by the 
MOH? How many times in your entire life alltogether?  n (0: never)  
23
9 health syst 
Did you ever go abroad for medical care, on your own initiative and paid for by 
yourself? How many times alltogether in your entire life?  n (0: never)     (all men: → hp15) 
24
0 gyne [Women] Did you take oral or injectable contraceptives during the past month? 
1: oral; 
2 injectable;  
3: no 
24





[Women] How many times did you have a screening test for cervical 
abnormalities such as a pap smear in the past 10 years ?   n (0 = never) 
24
3 screening [If >1 pap smear test]  When did you have your last pap smear test done? 
1: less than 3 years ago;  
2: between 3-10 years ago;  
3: more than 10 years ago 
24
4 screening 
[Women] Has a health professional ever examined your breast to screen for a 
disease? When?  
1: never;  
2: less than 3 years ago;  
3: between 3-10 years ago;  
4: more than 10 years ago 
24
5 screening 
[Women] Did you ever do a mammograhy (xray) or ultrasound of your breast? 
When? 
1: never;  
2: less than 3 years ago;  
3: between 3-10 years ago;  
4: more than 10 years ago 
24
6 screening 
[Women] Has anyone in your direct family (grand-mothers, mother, sisters, 





[All] Did you ever do a test to look for blood in your stools to screen for 
colon/intestine disease When? 
1: never;  
2: less than 3 years ago;  
3: between 3-10 years ago;  
4: more than 10 years ago 
24
8 HP 
During the past 12 months, did a health officer advise you about smoking, 





During the past 12 months, did a health officer advise you about your diet, 





During the past 12 months, did a health officer advise you in relation to weight 






During the past 12 months, did a health officer advise you about the need to 






During the past 12 months, did a health officer advise you about the need to limit 





Before you came to this study, had you ever heard of the Unit for Prevention and 




4 media Do you listen to the radio? 
1: every day;  
2: a few days per week;  
3: i rarely or never listen to the radio at home;  




When you listen to the radio, how often do you listen to SBC radio (excluding 
Paradise FM or other radio channels)? 
1: i often listen to SBC radio;  
2: rarely;  
3: never; 
4: i don't have a radio at home 
25
6 media 
In the past 12 months, can you remember to have listened to a program on 
health, particularly cardiovascular disease, smoking, blood pressure, diabetes or 
diet on SBC radio? 
1: yes;  
2: no;  
3: i never or rarely listen to SBC radio 
25
7 media How often do you watch TV at home? 
1: every day;  
2: a few days per week;  
3: rarely or never;  
4: i dont have a TV at home 
25




9 media When you watch TV at home, how often do you watch SBC? 
1: i watch SBC always/most of the time;  
2: often;  




In the past 12 months, can you remember to have watched a  program on 
cardiovascular disease, smoking, blood pressure, diabetes or diet on SBC TV? 
1: yes;  
2: no;  
3: i never of rarely watch SBC TV 
26
1 media 
Do you like to watch TV programs or listen to radio programs/magazines related 
to health? 
1: yes, i am interested a lot;  
2: yes, i am interested a little;  
3: no, i am not too interested  
26
2 media How often do you read local  daily newspapers? 
1: every day or almost every day 
2: a few times per week 
3: rarely or never 
26
3 media How often do you read local  weekly newspapers? 
1: every week or almost every week 
2: a few times per month 
3: rarely or never 
26
4 KAP CVD 
Let's speak now of some medical conditions.  




5 KAP CVD 
Do you know someone in your family or among your friends who has had a heart 
attack? 
1: no;  
2: yes, someone in my family;  
3: yes, a friend;  
4: yes,  in my family and among friends 
26




7 KAP CVD 
Do you know someone in your family or among your friends who has had a 
stroke? 
1: no;  
2: yes, someone in my family;  
3: yes, a friend;  
4: yes, in my family and among friends 
26
8 KAP CVD 
Do you think that your lifestyle and you diet can have an impact on your health 
later? 
1: yes, i think my lifestyle has a lot of impact 
on my health;  
2: yes, it has some impact;  
3: no, it has not much impact 
26
9 KAP CVD 
What best describes your attitude and actions regarding taking regular PA or 
having a balanced diet during the past 6 months? 
1: i didn't think much of it;  
2: i think if it but i didn't take action;  
3: i took action but i did not sustain it;  





Finally, we would like to ask you a few questions on how we could possibly 














on Do you use Internet with your phone?  
1: yes, every day 
2: yes, on some days 
3: yes, rarely 





Do you have a tablet or computer (your own or that you can use whenever you 
want outside of work)?  
1: computer 
2: tablet 





on Do you use Internet with a computer or tablet (outside of work)?  
1: yes, every day 
2: yes, on some days 
3: yes, rarely 











on Would you like to receive sms (text) on your phone related to health? 
1: yes 
2: no 




on Would you like to receive emails related to health? 
1: yes 
2: no 
3: i don't know 
27
8 other studies 
Would you agree to participate in further studies of follow up related to 




9 clinic Arm cirumference (cm) n 
28
0 clinic Height measured (cm) n 
28
1 clinic Weight asked (before measuring weight) n 
28
2 clinic Weight measured (kg) n 
28
3 clinic BMI based on wei and hei (to be used in most analyses) n 
28
4 clinic Waist (cm) n 
28
5 clinic Hip (cm) n 
28
6 clinic Cuff used l; m 
28
7 clinic sys at entry (by secretary, see time entry) n 
28
8 clinic dia at entry (secretary) n 
28
9 clinic pulse  at entry (secretary) n 
29
0 clinic officer administering questionnaire 
rm, jl, gem (ganyor mangroo); gm (gina 
michel), bf, vb, pb 
29
1 clinic sys 1 by nurse , during questionnaire n 
29
2 clinic dia 1 by nurse , during questionnaire n 
29
3 clinic pulse 1 by nurse , during questionnaire n 
29
4 clinic sys 2 by nurse , during questionnaire n 
29
5 clinic dia 2  by nurse , during questionnaire n 
29
6 clinic pulse 2 by nurse , during questionnaire n 
29
7 clinic sys 3 by nurse , during questionnaire n 
29
8 clinic dia 3 by nurse , during questionnaire n 
29
9 clinic pulse 3 by nurse , during questionnaire n 
30
0 clinic mean sys2 + sys3 n 
30
1 clinic mean dia2 + dia3 n 
30
2 clinic mean pulse2 + pulse3 n 
30
3 clinic SBP taken just after standing up 3 times from chair, 1 minute after BP3 n 
30
4 clinic DBP taken just after standing up 3 times from chair, 1 minute after BP4 n 
30
5 clinic pulse taken just after standing up 3 times from chair, 1 minute after BP5 n 
30
6 clinic 
first SBP taken by doctor before leaving study center, after all other 
measurements, often 2-4 hours after entry in study, e.g. beteen 8am - 1 pm n 
30
7 clinic first DBP taken by doctor before leaving study center  n 
30
8 clinic first pulse taken by doctor before leaving study center  n 




0 clinic second DBP taken by Dr n 
31
1 clinic second pulse taken by Dr n 
31
2 clinic 
number times standing up from chair, by nurse, at end of questionnaire, just after 
BP3 (and before BP4) n 
31
3 clinic reason for failing the test text 
31
4 clinic grip test 1, conducted at end of questionnaire, by nurse n 
31
5 clinic grip test 2, conducted at end of questionnaire, by nurse n 
31
6 clinic 
grip test 3, conducted at end of questionnaire, by nurse, at 15-30 second 
intervals n 
31
7 clinic failed test, or done on left hand text 
31
8 clinic reason to fail test  text 
31
9 clinic officer who administered BIA Omron and ultrasound foot Sahara text 
32
0 clinic weight using Omron BIA BF 508 n 
32
1 clinic bmi using Omron BIA n 
32
2 clinic fat percent using Omron BIA n 
32
3 clinic muscle percent using Omron BIA n 
32
4 clinic resting metabolic rate using Omron BIA n 
32
5 clinic visceral fat using Omron BIA n 
32
6 clinic BIA METS reactance n 
32
7 clinic BIA METS resistance n 
32
8 clinic BMD using Sahara ultrasound n 
32
9 clinic T score using Sahara ultrasound n 
33
0 clinic ethnicity assessed by Dr (same, PB) b; m, w, c(hin), i(nd) 
33
1 clinic heart murmur by stethoscope assessed by Dr (same PB) text 
33
2 clinic heart rythm by ECG Omron assessed by Dr (same, PB) text 
33
3 clinic extrabeats by ECG monitor Omron HCG 801 E (assessed by PB) text 
33
4 clinic 
Referal to HC or specialist for some medical problem that require further medical 
assessment 1:yes; 2: no 
33
5 clinic Where particiapant was referred text 
33
6 clinic Condition needing refereal text 
33
7 lab Officer doing blood test text 
33
8 lab fasting 1:yes; 2: no 
33
9 lab time blood taken hh:mm 
34
0 lab chol -lab Victoria n 
34
1 lab hdl - lab Victoria n 
34
2 lab trig - lab Victoria n 
34
3 lab ldl reagents (often not possible) - lab Victoria n 
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34
4 lab calcium - lab Victoria n 
34
5 lab crp - lab Victoria n 
34
6 lab creatinine - lab Victoria n 
34
7 lab uric acid - lab Victoria n 
34
8 lab a1c measured by laboratory of Victoria n 
34
9 lab a1c measured with A1cNow Bayer n 
35
0 lab glucose plasma mesured on plasma by lab Victoria n 
35
1 lab glucose mesured on capillary blood with Contour Bayer n 
35
2 lab glucose measured with Contour Plus (Praslin, n~100) n 
35
3 lab 
glucose measured by laboratory, but with values with Contour for 12 missing 
plasma values  n 
35
4 lab 
a1c measured with lab Victoria but with ~20 values with A1cNow when a1c lab 
was missing n 
35
5 lab 
a1c measured with A1cNow but with  ~20 values with a1c clin when A1cNow 
was missing n 
35
6 lab 
diabetes based on glucose >=7.0 on gluc plsma (or contour if plasma missing) or 
glucrxnow==1 1 if diabes with this criterion 
35
7 lab 
diabetes based on a1c clin >=6.5 or a1cnow if a1c clin missing (~20) or 
glucrxnow==1 1 if diabes with this criterion 
35
8 lab 
diabetes based on a1c now >=6.5 or a1c lab if a1cnow missing (~20-30) or 
glucrxnow==1 1 if diabes with this criterion 
35
9 lab number urine miction at survey since participant woke up n 
36
0 lab menstruation 1:yes; 0: no 
36
1 lab glucosuria (Siemens Multistix 10 SG) neg, tr, +, +++ 
36
2 lab ketones  (Siemens Multistix 10 SG) neg, tr, +, +++ 
36
3 lab proteinuria (Siemens Multistix 10 SG) neg, tr, +, +++ 
36
4 lab blood (Siemens Multistix 10 SG) neg, tr, +, +++ 
36
5 lab leucocytes (Siemens Multistix 10 SG) neg, tr, +, +++ 
36
6 lab density (Siemens Multistix 10 SG) 1000-1030 
36
7 lab pH(Siemens Multistix 10 SG) 5.0-8.5 
36
8 lab bilirubin (Siemens Multistix 10 SG) neg, +, +++ 
36
9 lab urobilinogen 0.2- >8 
37
0 lab nitrites neg, pos 
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Appendix 3. Data entry form for measurements 
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Appendix 4. Selection of participants and methods 
 
Selection of the participants 
 Assumptions considered for the selection of the eligible participants 
 A maximum of 20 participants could be seen every day considering that the survey team included 5 persons and since 
examination of each participant takes 2 hours (without waiting time).  
 The number of eligible participants invited each day was progressively adjusted over the first 3 weeks so that up to 20 
participants could be seen every day. Since letters were sent 3 weeks in advance, the response time to adjust for the optimal 
number of eligible participants to be seen each day was delayed by a few weeks. 
 All eligible participants were invited to attend the survey through a personalized letter on a specific date. Eligible participants 
were informed that they could call to change their appointment. 
 The total number of days allocated to the survey was limited to 12 weeks in Mahe and 2 weeks in Praslin/La Digue. 
 Because participants needed to be fasting (blood glucose measurement), participants were asked to attend early in the 
morning, between 6:30 am and 10:00 am.  
 Participants were informed that they would be served a breakfast at the study center after blood collection. 
Sample size and sample strategy 
• The goal was to examine approximately 150 persons within each sex‐ and 10‐year category (i.e. age categories 25‐34, 35‐44, 45‐
54, and 55‐64 for both men and women), hence a goal of 1200 participants alltogether.  
• This number (150 participants per each sex and 10‐year category) was chosen because it allows sufficiently precise estimates 
for blood pressure and blood lipids (within each of the eight age and sex categories, as well as for estimates in the total 
population aged 25‐64). 
• Assuming a worst scenario of a participation rate of 50‐60%, the requested total sample of eligible participants was set at 
n=3200. 
Selection of eligible participants 
•  A sex‐ and age‐stratified sample was drawn from the entire population of Seychelles aged 25‐64 years. 
•  The sex‐and age stratified random sample was prepared by the principal statistician of the National Bureau of Statistics (NBS, 
Helena Deletourdis). 
•  The sample initially included 3200 persons with 400 persons randomly selected in each sex and 10 year age categories. 
•  We excluded persons of non Seychellois descent (naturalization or marriage with a Seychellois person, based on their national 
identity number, n=457). 
•  We also excluded persons found to be dead, bfore and during the survey, by linkage with vital statistics (n=28), persons 
currently in prison (n=15), persons living abroad (n=16), persons who had moved to another island (n=16), and persons living in 
remote islands of the archipelago (n=5). 
•  When the exact dates to conduct the survey were known, we excluded fixed numbers of randomly selected eligible persons in 
order to not exceed the total numbers of eligible participants who could possibly be seen within the given time periods 
allocated to the survey (i.e. between 23 September and 20 December in Mahé and between 17 and 28 February 2014 in Praslin 
and La Digue).  
•  In the final participation rate, we exluded 176 persons for whom the letters of invitation were returned unopened with the 
mention “unknown addressee”, which most likely represent persons who had moved to other (unknown) addresses. 
•  This left 1702 eligible persons and 1240 participants, an overall participation rate of 72.9% overall.  
Strategies to increase the participation rate 
•  We used several strategies to increase the participation rate.  
•  All participants were offered the possibility to re‐schedule their visit at another date. 
•  District administrators were contacted every week to help provide contacts of non‐participants. 
•  Announcements were aired every week on the national radio (SBC) with the names of eligible participants who did not attend 
the survey, and inviting them to call the study center or just attend the survey at any other date at their convenience. 
•  A few further announcements were aired on the national radio at the end of the survey to further ask non‐participants to 
attend the survey on a few catch up days organized after the end of the survey.  
•  Several general programs on the survey were aired on the radio and on the main TV news bulletin (which captures a very large 
audience in Seychelles) to publicize the survey. 
•  All participants were informed, in their invitation letter, that they would receive a voucher allowing to buy food for the value of 
SR 200 in a large supermarket (~US$ 20, approximately corresponding to the daily wages for a low skilled worker), provided by 
Seychelles Trade Company. The voucher was deemed to cover for transport costs and time used to attend the survey. 
•  Participants were given a medical certificate to justify their absence of work. 
Questionnaire 
•  A structured questionnaire was administered face‐to‐face to the participants by the survey officers (senior nurses) in a secluded 
and quite room. 
•  The questionnaire was applied in Creole but some participants preferred speaking in English. 
•  Several questions on lifestyle (tobacco, alcohol, nutrition, physical activity, etc) came from the WHO STEP instrument [17]. 
•  Several questions on quality of life and frailty came from established instruments, e.g. the SF12 questionnaire [18‐19] and the 
SHARE instrument [20]. The SF12 (12‐Item Short Form Health Survey) is broadly used and was developed for the Medical 
Outcomes Study (MOS), a multi‐year study of patients with chronic conditions. The instrument was designed to reduce the 
respondent burden while achieving minimum standards of precision for purposes of group comparisons involving multiple 
health dimensions in different populations. 
•  Questions on KAP on NCDs, nutrition, use of health services, and exposure to mass media were locally developed and pre‐
tested before the survey. 
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•  Current and ideal body image, and body image discrepancy, was assessed using a nine‐silhouette rating scale developed tor 
multi‐ethnic purposes (Pulvers KM et al. Development of a culturally relevant body image instrument among urban African 
Americans. Obesity Obes Res. 2004;12:1641‐51). 
Clinical investigations 
•  Blood pressure was measured 5 times (once at arrival to the survey center, 3 times during the interview, and once before 
leaving the study center). 
•  BP was measured after a 5 minute rest, using a validated automated device (Omron M3) with a cuff of appropriate size for the 
arm circumference (large cuff for arm circumference ≥32 cm). 
•  Measurement of weight with an electronic scale (Seca), height (stadiometer Seca), and waist followed standardized methods. 
•  Anthropometric measurements. Percent fat and abdominal fat was measured by bio‐impedance using a body composition 
monitor (BF 511, Omron Healthcare). Given entry of height and sex, the instrument provides measurements for BMI, percent of 
total fat (normal values: 8‐22%, women: 21‐34%), percent of skeletetal muscle mass (normal values 33% to 39% in men and 
35%‐30% in women), precent of visceral fat and resting metabolic rate. Imprecision of measurement of both fat and muscle is 
reported to be <3%. The instrument is valid for persons aged 18 to 80 years and is clinically validated according to the 
manufacturer. 
•  Handgrip strength test, using a precision hydraulic hand dynamometer (Baseline Hydraulic Hand Dynamometer, 
FabricationEnterprises FEI, White Plains, New York). The subject holds the dynamometer in the dominant hand, with the arm at 
a right angle and the elbow by the side of the body. When ready the subject squeezes the dynamometer with maximum 
isometric effort for about 3 seconds. No other body movement is allowed. The test was run 3 times, with at least 15 seconds 
recovery between each effort. The values listed below give a guide to expected scores for adults (average of the best score). 
•  Chair stand test. The chair stand test is a physical performance test used to assess lower‐extremity function. Lower‐extremity 
function has been shown to predict subsequent development of disability because it reflects the effects of chronic diseases, 
coexisting conditions, and overall physiologic decline. A 5 time repetition test, as done in the survey, is a measure of strength.  
•  Procedure: The participant is seated on a standard solid and stable chair without arms. After having explained and 
demonstrated the test to the participant, the participant is asked to stand up without using his/her arms, returning completely 
to the correct starting seating position after each of the 5 repetitions. At the command “Ready, Set, Go” the tester begins 
timing by starting the stopwatch. The observer counts each chair stand out loud when the subject is in the standing position 
and provides continuous verbal encouragement during the test. 
•  Bone mass density was measured at the level of the calcaneus (heel bone) with an ultrasound system (Sahara Clinical Bone 
Sonometer, Hologic, USA). The system performs a quantitative ultrasound measurement of the calcaneus (heel bone) which 
can be used, in conjunction with other clinical risk factors, as an aid to the diagnosis of osteoporosis and medical conditions 
leading to reduced bone density, and ultimately in the determination of bone fracture risk. Sahara measures the speed of 
sound (SOS, in m/s) and broadband ultrasonic attenuation (BUA, in dB/MHz) of an ultrasound beam passed through the 
calcaneus, and combines these results linearly to obtain the Quantitative Ultrasound Index (QUI). The output is also expressed 
as a T‐score (difference between a given patient’s results and mean results for a young adult, in SD units) and as an estimate of 
the Bone Mineral Density (BMD, in g/cm2) of the calcaneus as would be measured by Dual Energy X‐ray Absorptiometry 
(DEXA). The WHO criteria classify patients with BMD values more than 2.5 SDs below the young adult mean (T‐score below ‐2.5) 
as “osteoporotic”, and patients with T scores between ‐1 and ‐2.5 as “osteopenic”. 
•  Procedure: Ultrasound measurement is performed with the patient seated, and his/her foot positioned and secured in the 
Sahara system using a positioning aide. After the patient’s foot is secured, a pair of soft elastomer pads is brought into contact 
with opposite sides of the patient’s heel by means of a motorized caliper mechanism. Each of the elastomer pads are 
acoustically coupled to the heel and to a sound transducer using ultrasound coupling gel. Inaudible high frequency sound 
waves, produced by one of the sound transducers, are transmitted through the heel and received by the opposite transducer. 
Quantitative parameters describing the speed and attenuation of the sound waves in the heel are measured.  
•  A 30‐second one lead electrocardiographic recording was performed in all participants to assess selected rhythm abnormalities 
e.g. atrial fibrillation, ventricular ectopic beats, etc (Heart Scan HCG 801‐E, Omron Healthcare, The Netherlands). 
Blood tests 
•  Venous blood was collected at the study center using a venipuncture set (Venofix green, Luer 21G, Braun, Germany) equipped 
with a Sarstedt multiadapter for S‐Monovette (Sarstedt, Germany). This system is optimal to prevent blood spillage and avoid 
contact of health staff with blood. 
•  For each participant, the following biological samples were collected: 1 Sarstedt serum Monovette of 9 ml, 1 Sarstedt EDTA 
Monovette of 9 ml, 1 yellow tube of 2.5 ml for plasma glucose (sodium fluoride and potassium oxalate, ISS), later replaced with 
2.5 tubes (BD Plymouth, UK), and 1 violet tube of 2.5 ml EDTA tube (BD Plymouth, UK) for analysis of A1c on whole bood. 
•  Capillary blood was also taken from each participant at the fingertip with an automatic lancing device (Glucolet 2, Bayer, 
Germany) with disposable lancets (Ames Minilet Lancets, Bayer). 
•  Capillary blood was immediately tested at UPCCD for glucose with a glucometer (Ascensia Contour, Bayer) and for A1c 
(A1cNow+, Bayer). Results are obtained within 30 seconds (Contour) and 5 minutes (A1c). 
•  Blood sample tubes were labeled only with the participants’ ID numbers. All tubes of a same participant were inserted in a 
sealed plastic envelope (Topgrip) on which the participant’s number was written in large characters. 
•  Reserve samples of serum/plasma were kept frozen at minus 80 Celsius at the Seychelles Hospital, but can be transferred in 
freezers at minus 25 at UPCCD when needed. The freezers at UPCCD are equipped with a temperature monitoring system. 
•  Blood samples are expected to be deleted after a period of 10 years. 
•  Centrifugation of blood was done at the Public Health Laboratory: 1 serum Monovette of 9 ml was aliquotted in 2 microtubes 
with caps (Sarstedt, Germany) of 1.5 ml with 1 ml of serum, while 1 Monovette EDTA 9 ml was aliquotted in 1 Eppendorf of 1.5 
ml with 0.5 ml of buffy coat and in 2 microtubes of 1.5 ml with caps (Sarstedt) with 1 ml of plasma. 
•  The following blood tests were performed within 2‐3 hours of blood collection at the clinical laboratory of the Seychelles 
Hospital: total cholesterol, HDL‐cholesterol, triglyceride, glucose, creatinine, uric acid, calcium, CRP (all these tests from 1 tube 
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with 1.5 ml serum), glucose (from yellow tube with sodium fluoride and potassium oxalate), A1c (violet EDTA tube). Insulin was 
analyzed 3 months later from one 1.5 ml microtube of serum. 
•  All analyses, except insulin and A1c, were done using a fully automatic analyzer Konelab 30i (Finland) with reagents from 
Thermo Fischer Scientific (USA). 
•  All tests performed using Konelab 30i were checked with controls on a daily basis.  
•  Glucose measurement used glucose oxydase (GOD) and a modified Trinder color reaction catalysed by the enzme peroxdase 
(POD). Imprecision is <3% of total CV at average glucose level (e.g. repeatability within run CV 0.7% + between device CV 1.9% 
at mean of concentration of blood glucose of 4.3 mmol/l). 
•  Cholesterol was measured after enzymatic hydrolysis by cholesterol esterase to cholesterol and free fatty acids, and free 
cholesterol oxidized by PEG cholesterol oxydase in peroxide, and then submitted to peroxidase to form a chromophore. 
Imprecision is <3.5% total CV, e.g. repeatability (within run) of 0.9% CV + within device (total) 1.4% CV at concentration of 
cholesterol of 5.2 mmol/l.  
•  HDL‐cholesterol was measured with an enzymatic colorimetric test after precipitation of non HDL lipoproteins. The cholesterol 
concentration of HDL‐C is determined enzymatically similary as cholesterol (above). Imprecision is <4% of total CV, e.g. 0.5% CV 
within run + 1.1% CV between run + 1.6% CV between day; total %CV 2.0 at HDL concentration of 1.26 mmol/l. 
•  Triglycerides were measured by hydrolysis by lipase (LPL) to glycerol and fatty acids, glycerol is phosphorylated to glycerol‐3‐
phosphate (by GK), then oxidized to hydrogen peroxide (GPO and POD) to form a quinoneime dye. Imprecision is <4% of total 
CV, e.g. 0.7% CV repeatability (within run) and CV 2.0% within device (total) at a concentration of triglyceride of 2.07 mmol/l. 
•  Calcium was measured based on highly coloured complex with Arsenazo III at neutral pH, measured at 660 nm. Imprecision is 
<3% CV 0.8% within run repeatability and CV 1.5% within device at calcium level of 2.10 mmol/l. 
•  Uric acid was measured after oxidation to allantoin with uricase and to indamines with POD. Imprecision is <4% total CV, e.g. 
0.8% CV repeatability (within run) + 2.3% CV within device (total) at a concentration of 70 µmol/l. 
•  Creatinine was measured with the Jaffé method. Imprecision is <5%, e.g. CV 1.1% repeatability within run + CV 2.0% within 
device at concentration of creatinine of 105 mmol/l.  
•  CRP was based on an immunoturbidimetric method, with measuring range between 6 and 636 mg/l. Imprecision is <3.2% total 
CV, e.g. 1.75% CV within run+ 2.4% CV between day at a concentration of CRP of 30 mg/l. 
•  A1c was analyzed with a fully automated analyzer (D‐10, Bio‐Rad, Hercules, CA, USA). TheD‐10 Hemoglobin A1c Program utilizes 
principles of ion exchange high performance liquid chromatography (HPLC). The D ‐10 Haemoglobin A1c Program is certified by 
the NGSP as having traceability to the DCCT reference method. Precision is CV 0.78 within run, 0.68% CV between day, 0.52% 
CV between run, total precision 1.16% CV. Controls with a standard were performed once monthly. 
•  Insulin was analyzed with an automatic analyzer (Siemens Immulite 1000) using a solid‐phase, enzyme‐labeled chmiluminescent 
immunomtric assay. Incubation time of 60 minutes. Range: 2‐300 µlU/ml. Median value in healthy volunteers is around 9 
µlU/ml. Precision is CV 6.4% within run and 8.0% CV total at low mean values. Control with a standard was done approximately 
once monthly. 
Urine tests 
•  Urinalysis was tested semi‐quantitatively with teststrips (Multistix 10SG, Siemens) for 10 urine indicators including glucose, 
ketone, protein, blood, leucoytes, nitrites, specific gravity, bilirubin, urobilinogen, and pH. 
•  A sample of urine was collected in 1 microtube of 2 ml for later analysis of Na, K, and creatinine. 
•  Na/K in urines were measured with the fully automated Konelab 30i analyzer (Thermo Scientific, Finland) using an ISE Calibrator 
(Ion Selection Electrodes). Control with a standard was done every day. 
•  The anonymized electronic database, after adequate data cleaning, as well as all reports deriving from the surveys, will be kept 
at the Ministry of Health for at least 10 years and will also be made available to the Seychelles National Archives. 
Communication of the results to the participants 
•  Before being discharged from the study center, all participants received information on their own results, and relevant advice, 
from the medical doctor of the survey. 
•  Participants with a newly found abnormal medical condition received a referral form signed by the doctor of the survey (a copy 
of which is kept at UPCCD) and were advised to go to a health center or to a specialist clinic to confirm or manage the 
condition. 
•  Participants who presented a serious medical condition were sent to the casualty for further diagnosis or care. 
•  A letter with selected results (blood pressure, BMI) and selected laboratory results (blood lipids, uric acid, and creatinine) was 
sent to each individual participant shortly after the visit to the survey center, which color marking of abnormal results that 
would need further confirmation. The letter included a phone number of the study center to call for any further information. 
 
